



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

## Impact of alternative diagnostic labels for melanoma in-situ on management choices and psychological outcomes: An online randomised study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-089558
Article Type:	Protocol
Date Submitted by the Author:	03-Jun-2024
Complete List of Authors:	<p>Wu, Zhuohan; The University of Sydney, Sydney School of Public Health, Faculty of Medicine and Health</p> <p>Elder, David; Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine</p> <p>Ferguson, Peter M.; Melanoma Institute Australia; Royal Prince Alfred Hospital and NSW Health Pathology, Tissue Pathology and Diagnostic Oncology</p> <p>O'Brien, Blake; Sullivan Nicolaides Pathology, Surgical Pathology</p> <p>Barnhill, Raymond; Paris Sciences and Lettres Research University, Department of Translational Research</p> <p>van Akkooi, Alexander C.J.; Melanoma Institute Australia</p> <p>Low, Donald; Cancer Voices New South Wales</p> <p>Low, Cynthia; Cancer Voices New South Wales</p> <p>Davies, Elspeth; Patient Researcher, Cambridge</p> <p>Liu, Sherrie; Health Consumers New South Wales</p> <p>Lewis, Stacey; Health Consumers New South Wales</p> <p>Spongberg-Ross, Bella; Health Consumers New South Wales</p> <p>Bell, Katy; The University of Sydney; Wiser Healthcare Research Collaboration</p> <p>Nickel, Brooke; University of Sydney, Sydney School of Public Health, Faculty of Medicine and Health; Wiser Healthcare Research Collaboration</p> <p>boroumand, farzaneh; The University of Sydney</p> <p>Scolyer, Richard; The University of Sydney</p> <p>Adamson, Adewole S.; Austin, Department of Internal Medicine; The University of Texas at Austin Dell Medical School,</p> <p>Emery, Jon; University of Melbourne, General Practice and Primary Care Academic Centre</p> <p>Parker, Lisa; University of Sydney</p>
Keywords:	<p>Dermatological tumours &lt; DERMATOLOGY, Adverse events &lt; THERAPEUTICS, Clinical Decision-Making, Surgical dermatology &lt; DERMATOLOGY, Surgical pathology &lt; PATHOLOGY, Patient-Centered Care</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Impact of alternative diagnostic labels for melanoma in-situ on management choices and psychological outcomes: An online randomised study.**

Zhuohan Wu<sup>1</sup>, Brooke Nickel<sup>1,2</sup>, Farzaneh Boroumand<sup>1,3</sup>, David Elder<sup>4</sup>, Peter Ferguson<sup>5,6</sup>, Richard A. Scolyer<sup>5,6,7,8</sup>, Blake O'Brien<sup>9</sup>, Raymond Barnhill<sup>10</sup>, Adewole S Adamson<sup>11</sup>, Alexander C.J. van Akkooi<sup>5,12</sup>, Jon Emery<sup>13</sup>, Lisa Parker<sup>14,15</sup>, Donald Low<sup>16</sup>, Cynthia Low<sup>16</sup>, Elspeth Davies<sup>17</sup>, Sherrie Liu<sup>18</sup>, Stacey Lewis<sup>18</sup>, Bella Spongberg-Ross<sup>18</sup>, Katy JL Bell<sup>1,2</sup>

<sup>1</sup>Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

<sup>2</sup>Wiser Healthcare Research Collaboration, Sydney, NSW, Australia

<sup>3</sup>School of Mathematical and Physical Sciences, Macquarie University, NSW, Australia

<sup>4</sup>Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia

<sup>5</sup>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

<sup>6</sup>Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia

<sup>7</sup>Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

<sup>8</sup>Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia

<sup>9</sup>Sullivan Nicolaides Pathology, Brisbane, QLD, Australia

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

23   <sup>10</sup> Department of Translational Research, Institut Curie, Paris Sciences and Lettres  
24   Research University, and Faculty of Medicine University of Paris Descartes, Paris,  
25   France

26   <sup>11</sup>Department of Internal Medicine (Division of Dermatology), The University of  
27   Texas at Austin Dell Medical School, Austin, TX 78701, USA

28   <sup>12</sup> Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology,

29   <sup>13</sup> Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia

30   <sup>14</sup> School of Pharmacy, Faculty of Medicine & Health, Charles Perkins Centre,  
31   University of Sydney, Australia

32   <sup>15</sup>Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia

33   <sup>16</sup> Cancer Voices New South Wales, NSW, Australia

34   <sup>17</sup> Patient Advocate, Cambridge, UK

35   <sup>18</sup> Health Consumers New South Wales, NSW, Australia

36

37   **Corresponding Author:** Katy Bell [katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au)

## Abstract

## Introduction

A diagnosis of melanoma in-situ presents negligible risk to a person's lifespan or physical wellbeing, but existing terminology makes it difficult for patients to distinguish these from higher risk invasive melanomas. This study aims to explore whether using an alternative label for melanoma in situ may influence patients' management choices and anxiety levels.

## Methods and Analysis

This study is a between-subjects randomised online experiment, using hypothetical scenarios. Following consent, eligible participants will be randomised 1:1:1 to three labels: "melanoma in situ" (control), "low-risk melanocytic neoplasm" (intervention 1) and "low-risk melanocytic neoplasm, in situ" (intervention 2). The required sample size is 1668 people. The co-primary outcomes are (i) choice between no further surgery or further surgery to ensure clear histological margins greater than 0.5mm, and (ii) choice between patient initiated clinical follow up when needed (patient-led surveillance) and regular routinely scheduled clinical follow-up (clinician-led surveillance). Secondary outcomes include diagnosis anxiety, perceived risk of invasive melanoma and of dying from melanoma, and management choice anxiety (after surgery choice and follow-up choice). We will make pairwise comparisons across the three diagnostic label groups using regression models (univariable and multivariable).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

59     **Ethics and Dissemination**

60     The study has been registered with the Australian New Zealand Clinical Trials  
61     Registry (ACTRN12624000740594). Ethics approval has been received from The  
62     University of Sydney Human Research Ethics Committee (2024/HE000019). Results  
63     of the study will be published in a peer-reviewed medical journal and a plain language  
64     summary of the findings will be shared on the Wiser Healthcare publications page  
65     <https://www.wiserhealthcare.org.au/category/publications/>.

67     **Strengths and Limitations of This Study**

- 68         • The randomised design will provide highly relevant evidence on potential  
69         impacts of alternative diagnostic labels for melanoma in situ to patients’  
70         decision-making and psychological outcomes.
- 71         • The study has been co-designed with consumers and clinicians to ensure labels  
72         and evidence are relevant to end-users.
- 73         • The large online randomised study will be representative of adults in the  
74         Australian community.
- 75         • The hypothetical nature of the study means it cannot capture experiences of  
76         patients after an actual melanoma in situ diagnosis, nor the impact on potential  
77         patients’ loved ones.
- 78         • The study does not explore the potential for recalibration of diagnostic  
79         thresholds using existing labels. This is an important area for further research.

## INTRODUCTION

Melanoma incidence and mortality trajectories in Australia and other countries show a classic epidemiologic signature of overdiagnosis<sup>1</sup>: steeply increasing incidence curves coupled with flat mortality trends<sup>2-6</sup>. While aging populations may lead to a small real increase in melanoma incidence<sup>7</sup>, much of the increase is likely overdiagnosis<sup>2-6, 2-6</sup>.

This appears to be largely driven by increased diagnosis of melanoma in situ<sup>2 4 8</sup>, which in Australia is now diagnosed over twice as frequently as invasive melanoma<sup>9</sup>. Similar findings have been found for melanoma in the US (diagnosed at least as frequently as invasive melanoma)<sup>3</sup> and Denmark (diagnosed over half as frequently as invasive melanoma)<sup>10</sup>.

Multiple evidence lines indicate that melanoma in situ is a risk factor for invasive melanoma rather than an obligate precursor<sup>3 9 11 12, 3 9 11 12</sup>. Overdiagnosis is partly driven by lowering the diagnostic threshold over the years, such that the same lesion that was called benign in the past, would now be labeled melanoma in situ<sup>12</sup>. Concerns about litigation may also be driving a tendency to interpret melanocytic lesions as a more severe diagnosis<sup>13</sup> particularly in partial biopsies or where the lesion extends to the surgical margins. Harms stemming from melanoma overdiagnosis include physical, psychosocial, and economic dimensions<sup>14</sup>. Physical harms can include overtreatment, repeat skin biopsies<sup>15</sup>, scarring<sup>15</sup>, pain, infection, and/or functional impairment. Psychological harms include anxiety and fear<sup>16 17</sup>, with many

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

patients perceiving they have a high risk of dying from melanoma, when their actual risk is much lower (and risk all-cause mortality is actually lower than the population average)<sup>18</sup>. These psychological harms can manifest as anxiety about being outdoors, fear of cancer recurrence, or guilt for past UV exposure causing melanoma<sup>5</sup>. Social harms include impacts of the diagnosis on loved ones, and on patients’ social networks<sup>15</sup>. Economic harms include treatment costs for the immediate diagnosis, and for future long term clinical surveillance. These incur substantial financial costs to both the health system and patient (as out-of-pocket costs), as well as opportunity costs for both clinician time and patient time. There is also a possible denial of life insurance as the person is now identified as a cancer survivor by many insurance companies (3).

One possible solution is to consider a new label for melanoma in situ without the word “melanoma”<sup>12</sup>. This might help patients recognize the lower risk of this type of lesion<sup>18</sup>, and help to reduce the potential psychological harm. It may also pave the way for the de-escalation of treatment <sup>19</sup> and surveillance<sup>20-22</sup>. Evidence from other cancer contexts, including thyroid<sup>23</sup>, breast<sup>24</sup>, and prostate<sup>25</sup> lesions, suggests that new diagnostic labels may beneficially impact psychological outcomes and management decisions<sup>26</sup>. We seek to build on these findings by investigating the potential impacts of new labels for melanoma in situ. To ensure relevance of our findings to end-users, we will test alternative labels for melanoma in situ that were chosen by our co-

Investigators representing clinicians, patients, and the public. Alternative label(s) need to be acceptable to both patients and clinicians, and convey the low, but not zero, risk of future invasive melanoma. This study aims to explore whether using an alternative diagnostic label to communicate a hypothetical melanoma in situ diagnosis influences management choice and level of anxiety among Australian adults.

## METHODS AND ANALYSIS

### *Study design*

An online randomised study of Australian community members will be run, with participants randomised to receive one of three hypothetical scenarios about the diagnosis of a melanoma in situ. Each group will be presented with a different diagnostic label, and we will survey participants about their preferred choices of management for that diagnosis, their level of anxiety about that diagnosis and their level of anxiety about their management choices.

This study is a between-subjects randomised online experiment. Following consent, eligible participants will be randomised 1:1:1 to “melanoma in situ” (control), “low risk melanocytic neoplasm” (intervention label 1), and “low risk melanocytic neoplasm, in situ” (intervention label 2). The co-primary outcomes and secondary outcomes will be compared across randomised groups.

There will be an equal probability of being assigned to each of the 3 groups, and we expect approximately equal numbers per group. We will use Qualtrics survey

1  
2  
3  
4143 software to randomly allocate participants into groups, present the scenarios, survey  
5  
6144 questions and collect data on the outcomes (Qualtrics, Provo, UT, 2020). Our  
7  
8  
9145 participants flow diagram present a summary of the randomisation of participants into  
10  
11  
12146 the allocated control and intervention arms (Figure 1).  
13  
14  
15147

16  
17148 ***Eligibility criteria***  
18

19  
20149 Participants will be eligible if they are: 40 years or older, understand written English,  
21  
22150 and reside in Australia. Participants will be excluded if they have a history of  
23  
24  
25151 melanoma (invasive or in-situ).  
26  
27  
28152

29  
30153 ***Recruitment and data collection.***  
31

32  
33154 Participants will be recruited via Qualtrics. Participants who agree to participate in the  
34  
35155 study will complete an online Qualtrics survey managed by the research team. Only  
36  
37  
38156 eligible participants will proceed to the randomisation step. The survey will capture  
39  
40  
41157 baseline data and characteristics of participants including socio-demographic details  
42  
43158 including their age, location, health literacy, and personal and family history of any  
44  
45  
46159 cancer, and participant responses on outcome measures. The survey questions are  
47  
48160 presented in the Supplement.

49  
50  
51161 All data will be collected via Qualtrics software and hosted on The University of  
52  
53162 Sydney secure server. Information will be de-identified and we will not be able to link  
54  
55  
56163 the survey back to participants. The non-identifiable data will be downloaded for  
57  
58  
59  
60

analysis and stored within The University of Sydney's Research Data Store.

### ***Determination of alternative labels to be tested.***

We undertook a targeted literature search in September 2023 by retrieving forward

and backward citation searches of four key papers on the topic (10,15,16,21). We

used the automated tool 'Spider Cite' (22) to identify records, and Covidence to to

screen title, abstract and full-texts (Veritas Health Innovation, Australia;

<https://www.covidence.org>). Of 593 unique records retrieved, we screened the full

text of 27, and included 7 papers describing 9 alternative labels (see Box 1).

Using short online questionnaires implemented in Qualtrics (Provo, UT: Qualtrics,

2020), we then ran three rounds of surveys with the 9 international Clinician co-

Investigators (with expertise in dermatopathology, dermatology, surgical oncology,

primary care, and radiation oncology), and 6 Patient/Public co-Investigators (two with

lived experience of a melanoma diagnosis and four without a history of melanoma) to

determine choice of alternative labels. This resulted in the final choice of two

alternative labels that we will test in the online survey: ***low-risk melanocytic***

***neoplasm*** and ***low-risk melanocytic neoplasm, in situ***.

### ***Interventions***

Participants will be randomised using Qualtrics randomisation software to receive one

of three hypothetical scenarios. They will not be blinded. In each scenario, the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

participant will be told that the results of their recent skin surgery indicates a particular diagnosis. Group 1 (the control group) will be told they have a *melanoma in situ*. Group 2 will be told they have a *low-risk melanocytic neoplasm*. Group 3 will be told they have a *low-risk melanocytic neoplasm, in situ*.

**Primary and Secondary Outcomes**

Primary and secondary outcomes are described in Table 1. The co-primary outcomes are (i) participant’s choice of surgical management option: no further surgery vs further surgery, and (ii) follow-up management option: patient led surveillance (self-skin examination with patient-initiated clinic visits) vs clinician led surveillance (six monthly routinely scheduled clinic visits). Secondary outcomes are: diagnosis anxiety, perceived lifetime risk of invasive melanoma, perceived lifetime risk of dying from melanoma, management choice anxiety, and open-text explanation of management choices (free text input).

**Sample size**

We estimated a sample size of 1668 participants with 556 participants per group in the study, which would provide 80% power (1 -  $\beta$ ) to detect a pairwise difference in the proportion of choosing no further surgery, and 89% power to detect a pairwise difference in the proportion in choosing patient-led surveillance as small as 10%. The assumptions are: 50% would choose no further surgery (most conservative

assumption) and 35%<sup>22</sup> would choose patient-led surveillance in the control label condition, a 5% dropout rate,  $\alpha = 0.05$ , the normal approximation to the binomial distribution, and the standard formula for comparing proportions in independent equal-sized groups.

210

### 211 *Analysis*

212 The analysis will focus on assessing the impact of different diagnostic labels for  
213 melanoma in situ on participants' psychological responses and healthcare decisions.  
214 Data analysts will be blinded to intervention assignment. For both co-primary  
215 outcomes, we will compare the proportion chosen for each management option. For  
216 first four secondary outcomes, we will compare summary statistical measures (means  
217 or medians) across randomised groups. For the last outcome, we will use thematic  
218 framework methods of qualitative data.

219

220 The analysis will adhere to the intention-to-treat principle, and participant data will be  
221 analyzed according to their randomly assigned diagnostic label group, regardless of  
222 adherence to the study protocol. The number of participant responses included in each  
223 analysis will be presented for each outcome. We will summarize categorical data for  
224 the randomised groups using counts and percentages, and continuous data using the  
225 minimum and maximum, mean, and standard deviation (SD) or median and  
226 interquartile range (IQR).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

227

228 Statistical analyses will be conducted within a superiority framework to make  
229 pairwise comparisons across the three diagnostic label groups. Binary outcomes will  
230 be analyzed using logistic regression. Continuous outcomes will be analyzed using  
231 linear regression. For the cancer worry outcome, we will compare changes in worry  
232 across randomised groups by including baseline scores as a covariate in the regression  
233 model. Effect estimates for all primary and secondary outcomes will be presented  
234 with associated 95% confidence intervals (CI). All hypothesis tests will be two-sided  
235 with a significance level ( $\alpha$ ) of 5%. The potential for participants' health literacy to act  
236 as an effect modifier of intervention effects will be explored.

237

238 We will estimate unadjusted and adjusted effects using the relevant regression model.  
239 These will include variables used in sampling strata: age, education, geographic  
240 location (by state/territory). Prognostic factors will be measured through the baseline  
241 questionnaire, and include baseline anxiety levels, sun exposure behavior, prior  
242 diagnosis of melanoma, diagnosis of melanoma in a family member. The effects of  
243 participants' health literacy on intervention effects will also be explored as a potential  
244 confounder.

245

246 ***Patient and public involvement***

247 Two authors have lived experience of a melanoma diagnosis, and four authors are

members of the public. Two authors are affiliated with Cancer Voices NSW, one author is a patient researcher from Cambridge UK, and three authors are affiliated with Health Consumers NSW.

## **Ethics and Dissemination**

Ethics approval of this project was provided by the University of Sydney on 06 May 2024 (No. 2024/HE000019). The study is registered with the Australian New Zealand Clinical Trials Registry (ID 386943). Updates to the protocol will be uploaded to the registry and identified by version number.

As this study is an online randomised experiment which includes a hypothetical scenario, we do not anticipate significant adverse events because of the trial interventions or conduct. Participants are reminded at several points before and after the study as part of the participant information, consent and debrief processes that the nature of the study is hypothetical, that none of the information relates to their actual health or wellbeing, and that researchers do not have access to their actual medical histories or information. The debriefing content also includes links to relevant resources for participants who wish to find out more.

The research team will have access to the final dataset. Access may be granted to other researchers on reasonable request. No contractual agreements limit the disclosure of data to other investigators. The findings of the study will be published in a peer-reviewed medical journal. A lay summary of the findings will be published via

permanent link at the Wiser Healthcare publications page.

**Conclusion**

This research protocol outlines a study that aims to investigate the impact of alternative diagnostic labels for melanoma in situ on healthcare decisions and psychological outcomes. The study was designed in accordance with SPIRIT guidelines and will be conducted in line with CONSORT guidance.

The potential significance of this study lies in its ability to impact clinical practice and policy by identifying alternative diagnostic labels for melanoma in-situ that are acceptable to patients, pathologists, and treating clinicians. Widespread adoption of new labels for low-risk melanocytic lesions that do not include the word “melanoma”, may mitigate the harms from overdiagnosis and overtreatment. Alternative labeling of melanoma in-situ may better inform patients about the low level of risk associated with the lesion, and allow appropriate de-escalation of treatment and surveillance options.<sup>18</sup> This would lessen burdens on individuals, their loved ones, clinicians, and health systems. Results may also provide evidence relevant to other low-risk conditions.

**Contributors**

ZW co-led drafting of the manuscript, led drafting of the study questionnaire and application to the Human Research Ethics Committee, and assisted with the targeted

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

literature review (full text screening and data extraction). BN and KB conceptualized the research, provided methodological expertise, and revised the manuscript draft. KB led the targeted literature review and the Clinician and Consumer Investigator survey to decide the choice of alternative labels, and co-led drafting of the manuscript. FB calculated the sample size. All authors read, contributed to, and approved the final manuscript.

### **Funding**

Funding for the study is provided by a National Health and Medical Research Council of Australia (NHMRC) Centre for Research Excellence Grant (2021/GNT2006545). Brooke Nickel is supported by a NHMRC Investigator Grant (2020/GNT1113532). RAS is supported by a NHMRC Investigator Grant (2022/GNT2018514). Katy Bell is supported by a NHMRC Investigator Grant (2019/GNT1174523). The University of Sydney is the Sponsor of the study. The funder and sponsor had no role in the study design, collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.

### **Declaration of Interests**

RAS has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 311 AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline.
- 312 AvA received Advisory Board/Consultancy Honoraria from 4SC AG, Amgen,
- 313 Bristol-Myers Squibb, Merck Serono-Pfizer, MSD-Merck, Neracare, Novartis, Pierre
- 314 Fabre, Sanofi, Sirius Medical, SkylineDX and Research Grants from Amgen, Merck
- 315 Serono-Pfizer, SkylineDX.
- 316 All other authors have no conflicts of interest to declare.

**References:**

1. Welch HG, Kramer Barnett S, Black William C. Epidemiologic Signatures in Cancer. *New England Journal of Medicine* 2019;381:1378-86.
2. Glasziou PP, Jones MA, Pathirana T, et al. Estimating the magnitude of cancer overdiagnosis in Australia. *Med J Aust* 2020;212:163-68.
3. Welch HG, Mazer BL, Adamson AS. The Rapid Rise in Cutaneous Melanoma Diagnoses. *N Engl J Med* 2021;384:72-79.
4. Adewole SA, Geetanjali N, Mark AJ, et al. Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method. *BMJ Evidence-Based Medicine* 2024;bmjebm-2023-112460.
5. Adamson AS, Suarez EA, Welch HG. Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. *JAMA Dermatol* 2022;158:426-31.
6. Mille Falk B, Emma Grundtvig G, John Brandt B. Overdiagnosis in malignant melanoma: a scoping review. *BMJ Evidence-Based Medicine* 2024;29:17.
7. Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. *The Lancet* 2023;402:485-502.
8. Whiteman DC, Olsen CM, MacGregor S, et al. The effect of screening on melanoma incidence and biopsy rates. *Br J Dermatol* 2022;187:515-22.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

336 9. Olsen CM, Pandeya N, Rosenberg PS, et al. Incidence of in Situ vs Invasive  
337 Melanoma: Testing the "Obligate Precursor" Hypothesis. J Natl Cancer Inst  
338 2022;114:1364-70.

339 10. Nielsen JB, Kristiansen IS, Thapa S. Increasing melanoma incidence with  
340 unchanged mortality: more sunshine, better treatment, increased diagnostic activity,  
341 overdiagnosis or lowered diagnostic threshold? Br J Dermatol 2024;ljae175.

342 11. Elder DE. Obligate and Potential Precursors of Melanoma. J Natl Cancer Inst  
343 2022;114:1320-22.

344 12. Semsarian CR, Ma T, Nickel B, et al. Do we need to rethink the diagnoses  
345 melanoma in situ and severely dysplastic naevus? Br J Dermatol 2022;186:1030-32.

346 13. Titus LJ, Reisch LM, Tosteson ANA, et al. Malpractice Concerns, Defensive  
347 Medicine, and the Histopathology Diagnosis of Melanocytic Skin Lesions. Am J Clin  
348 Pathol 2018;150:338-45.

349 14. Bell KJL, Nijsten T. Melanoma overdiagnosis: why it matters and what can be  
350 done about it. Br J Dermatol 2022;187:459-60.

351 15. Elspeth D. Informed by research, transformed by research. BMJ Evidence-Based  
352 Medicine 2024;29:62.

353 16. Bell KJL, Mehta Y, Turner RM, et al. Fear of new or recurrent melanoma after  
354 treatment for localised melanoma. Psycho-Oncology 2017;26:1784-91.

- 1  
2  
3  
4 355 17. Mahama AN, Haller CN, Labrada J, et al. Lived Experiences and Fear of Cancer  
5  
6 356 Recurrence Among Survivors of Localized Cutaneous Melanoma. *JAMA Dermatol*  
7  
8  
9 357 2024;160:495-501  
10  
11  
12 358 18. Patel VR, Roberson ML, Pignone MP, et al. Risk of Mortality After a Diagnosis  
13  
14 359 of Melanoma In Situ. *JAMA Dermatology* 2023;159:703-10.  
15  
16  
17 360 19. Zijlker LP, Eggermont AMM, van Akkooi ACJ. The end of wide local excision  
18  
19 361 (WLE) margins for melanoma ? *European Journal of Cancer* 2023;178:82-87.  
20  
21  
22 362 20. Moncrieff MD, Bastiaannet E, Underwood B, et al. Follow-up Schedule for  
23  
24 363 Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study):  
25  
26 364 An International Phase III Randomized Clinical Trial. *Annals of Surgery* 2022;276:  
27  
28 365 e208-e216.  
29  
30  
31 366 21. Lim W-Y, Morton RL, Turner RM, et al. Patient Preferences for Follow-up After  
32  
33 367 Recent Excision of a Localized Melanoma. *JAMA Dermatology* 2018;154:420-27.  
34  
35  
36 368 22. Drabarek D, Ackermann D, Medcalf E, et al. Acceptability of a Hypothetical  
37  
38 369 Reduction in Routinely Scheduled Clinic Visits Among Patients With History of a  
39  
40 370 Localized Melanoma (MEL-SELF): Pilot Randomized Clinical Trial. *JMIR Dermatol*  
41  
42 371 2023;6:e45865.  
43  
44  
45  
46  
47  
48 372 23. Nickel B, Barratt A, McGeechan K, et al. Effect of a Change in Papillary Thyroid  
49  
50 373 Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized  
51  
52 374 Crossover Trial. *JAMA Otolaryngol Head Neck Surg* 2018;144:867-74.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

375 24. McCaffery K, Nickel B, Moynihan R, et al. How different terminology for ductal  
376 carcinoma in situ impacts women’s concern and treatment preferences: a randomised  
377 comparison within a national community survey. BMJ Open 2015;5:e008094.

378 25. Berlin A, Ramotar M, Santiago AT, et al. The influence of the “cancer” label on  
379 perceptions and management decisions for low-grade prostate cancer. JNCI: Journal  
380 of the National Cancer Institute 2023;115:1364-73.

381 26. Nickel B, Moynihan R, Barratt A, et al. Renaming low risk conditions labelled as  
382 cancer. BMJ 2018;362:k3322.

383

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

**Box 1: Process to select alternative labels to melanoma in situ for testing**

- In the first-round surveys Clinician and Patient/Public co-Investigators indicated their ranking the 7 labels identified in the targeted literature search, and 2 additional labels in order of preference. The potential alternative labels from the literature search were: Melanocytic neoplasm of low malignant potential (8,24,25), Melanocytic neoplasm, Atypical neoplasm" (25), Severe or High-Grade Melanocytic Dysplasia, Superficial Atypical Melanocytic Proliferation of Uncertain Malignant Significance (SAMPUS) (26–28), Melanocytic Tumor of Uncertain Malignant Potential (MELTUMP), Melanocytoma (28). The two additional labels suggested by the research team were: low-risk melanocytic neoplasm and low-risk melanocytic lesion.
- In the second round surveys, co-Investigators indicated their preferred ranking of the top three choices from round 1 and two new labels suggested in round 1: Low-risk melanocytic neoplasm, Low-risk melanocytic lesion, and Melanocytic neoplasm of low malignant potential, Melanocytic intraepithelial neoplasia, and In situ melanocytic neoplasm.
- In the third round surveys, co-Investigators indicated their preferred ranking of the top two choices from round 2, and three new labels suggested in round 2: In situ melanocytic neoplasm, Low-risk melanocytic neoplasm, In situ melanocytic neoplasm, low risk, low-risk melanocytic neoplasm, in-situ, and dysplastic naevus. The two highest ranked labels, chosen as the alternative labels to test in the online

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

experiment, were: “*low-risk melanocytic neoplasm*” and “*low-risk melanocytic neoplasm, in-situ*”.

384

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

385 **Table 1. Participant characteristics and outcome measures.**


Variable	Measure
<b>Participant Characteristics</b>	
Melanoma risk	Melanoma risk prediction based self-assessed risk factors <sup>27</sup>
General mood and wellbeing.	WHO (Five) Well-Being Questionnaire. <sup>28</sup>
Medical minimiser/maximiser.	Single-Item Maximiser/Minimiser Elicitation Question (MM1). <sup>29</sup>
Health literacy.	Single Item Literacy Screener (SILS). <sup>30</sup>
Melanoma worry.	Direct choice between specified options, one choice possible.
Self-efficacy.	Generalized Self-Efficacy Scale (GSE). <sup>31</sup>
<b>Primary Outcomes</b>	
Co-primary outcomes are choices for two management decisions. 1. Choice of further surgery: • No further surgery • Further surgery to ensure margins >0.5mm from lesion on pathology 2. Choice of follow-up: • Patient led surveillance: self-monitoring with patient-initiated clinic visits as needed • Clinician led surveillance: six monthly routinely scheduled clinic visits	Direct choice between two management approaches for each co-primary outcome Choice of further surgery and choice of follow-up.
<b>Secondary Outcomes</b>	
Diagnosis anxiety.	Single-question Visual Analogue Scale (0-10). <sup>32</sup>
Perceived lifetime risk of invasive melanoma	Single-question Visual Analogue Scale (0-100)
Perceived lifetime risk of dying from melanoma	Single-question Visual Analogue Scale (0-100)

Management choice anxiety.	Single-question Visual Analogue Scale (0-10). <sup>32</sup>
Open-text explanation of management choice.	Free text (optional)

386

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**Figure 1. Study CONSORT flow diagram**

**Landing Page ✓**

**Effect of the label for a low risk melanocytic lesion on preferred management strategy: a randomised experiment.**

Thank you for your interest in our study about low-risk melanocytic lesion.

In this study, you will be randomised to be shown one of three hypothetical scenarios following surgery on a mole, which will be followed by questions about management options and anxiety.

The study is being conducted by a team of researchers from The University of Sydney School of Public Health. The team members are:

- Professor Katy Bell (School of Public Health at the University of Sydney)
- Dr Brooke Nickel (School of Public Health at the University of Sydney)
- Mr Zhuohan Wu (School of Public Health at the University of Sydney)

Taking part in the study involves completing one online questionnaire which will take approximately 10 minutes to complete.

Being in this study is completely voluntary and you do not have to take part. Your decision on whether to participate will not affect your current or future relationship with the researchers or anyone else at the University of Sydney.

Please take the time to read through the Participant Information Statement below.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

If you are interested in taking part in this study, you will be asked to consent to take part by ticking the 'yes' box at the beginning of the questionnaire. By giving your consent to take part in this study, you are telling us that you:

- ✓ Understand what you have read in the Participant Information Statement.
- ✓ Agree to take part in the research study as outlined in Participant Information Statement.
- ✓ Agree to the use of your personal information as described.

When you have consented, you will fill out an online questionnaire that asks a series of questions, such as:

- Demographic questions, such as age, education, income level and relationship status.
- General health and cancer related questions.
- Melanoma and other cancer history related questions.

You will be randomised to read one of three HYPOTHETICAL EXAMPLES (these are made up examples) in which different labels are used to explain a low-risk melanocytic skin lesion result. **Please note that you WILL NOT be receiving information or advice on any real mole check results or information about your actual health status.**

The hypothetical examples will be followed by questions about choice of management strategy and personal perspective.

**Pre-Survey PIS ✓**

1 **Effect of the label for a low-risk melanocytic lesion on management strategy: a randomised**  
2 **experiment**  
3  
4  
5

6 **PARTICIPANT INFORMATION STATEMENT**  
7  
8  
9

10 **(1) What is the study about?**  
11

12 You are invited to participate in a study that assesses how different labels given to an atypical mole  
13 (low-risk melanocytic skin lesion) affect a person’s anxiety and cancer concern, and their intention to  
14 undergo different treatment options. We are interested in a range of views and experiences.  
15  
16  
17  
18

19 **(2) Who is running the study?**  
20

21 The study is being conducted by a team of researchers and clinicians.  
22  
23 The team members are:  
24  
25 • Professor Katy Bell (School of Public Health at the University of Sydney).  
26  
27 • Dr Brooke Nickel (School of Public Health at The University of Sydney).  
28  
29 • Mr Zhuohan Wu (School of Public Health at the University of Sydney).  
30  
31 Professor Katy Bell is leading the study.  
32  
33  
34

35 **(3) What will the study involve for me?**  
36

37 If you agree to participate, you will complete an online questionnaire asking for some background  
38 information about yourself and your medical history. You will be randomised to be shown one of  
39 three hypothetical scenarios about low-risk melanocytic lesion results, which will be followed by  
40 questions about treatment choice, anxiety and cancer concern. After completing and submitting this  
41 questionnaire, there will be no further contact anticipated between yourself and the research team.  
42  
43  
44  
45  
46

47 **(4) How much time will the study take?**  
48

49 The study involves one online questionnaire which will take approximately 10 minutes to complete.  
50  
51  
52

53 **(5) Who can take part in the study?**  
54

55 Eligible participants will be people living in Australia aged 40 years or older with no prior history of  
56 melanoma. Participants must read and speak adequate English to be eligible.  
57  
58  
59  
60

**(6) Do I have to be in the study? Can I withdraw from the study once I've started?**

Being in this study is completely voluntary and you do not have to take part. Your decision whether to participate will not affect your current or future relationship with the researchers or anyone else at the University of Sydney. Submitting your completed questionnaire is an indication of your consent to participate in the study. You can withdraw your responses any time before you have submitted the questionnaire without giving a reason. Once you have submitted it, we will not be able to withdraw your responses due to their anonymous nature, and therefore we will not be able to tell which one is yours.

**(7) Are there any risks or costs associated with being in the study?**

There are no foreseeable risks involved if you participate in this study; however some participants may feel emotional. Participants who express or experience distress during the survey are not obligated to continue and can contact the Cancer Council helpline for support on 13 11 20 or [info@cancer.org.au](mailto:info@cancer.org.au). Please contact researchers via email [katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au) if you require further information or support. Aside from giving up your time, we do not expect that there will be any costs associated with taking part in this study.

**(8) Are there any benefits associated with being in the study?**

Findings from this study will provide much needed Australian-first data on the impact of different labels for a low-risk melanocytic skin lesion. That said, we cannot guarantee that you will receive any direct benefits from being in the study.

**(9) What will happen to the information about me that is collected during the study?**

By providing your consent, you are agreeing to us collecting personal information that you provide in your answers to the survey for the purposes of this research study. Your information will only be used for the purposes outlined in this Participant Information Statement, unless you consent otherwise. Your information will be stored securely and your identity/information will be kept strictly confidential, except as required by law. Study findings will be published as articles in academic journals, and presented at conferences, but you will not be individually identifiable in these publications. The research team will have access to the final trial dataset. Access may be granted to other researchers on reasonable request. Sharing research data is important for advancing knowledge and innovation. A de-identified set of the data collected in this study may be made

available for use in future research.

**(10) Can I tell other people about the study?**

Yes, you are welcome to tell other people about the study.

**(11) What if I would like further information about the study?**

When you have read this information, Professor Katy Bell will be available to discuss it with you further and answer any questions you may have. If you would like to know more at any stage during the study, please feel free to contact Prof Katy Bell on [katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au).

**(12) Will I be told the results of the study?**

You have a right to receive feedback about the overall results of this study. The results of the study and a plain language summary of the findings will be published on the permanent web page [wiserhealthcare.org.au/category/publications](https://wiserhealthcare.org.au/category/publications) after the study has been published in a medical journal.

**(13) What if I have a complaint or any concerns about the study?**

Research involving humans in Australia is reviewed by an independent group of people called a Human Research Ethics Committee (HREC). The ethical aspects of this study have been approved by the HREC of the University of Sydney. As part of this process, we have agreed to carry out the study according to the National Statement on Ethical Conduct in Human Research (2007). This statement has been developed to protect people who agree to take part in research studies. If you are concerned about the way this study is being conducted or you wish to make a complaint to someone independent from the study, please contact the university using the details outlined below. Please quote the study title and protocol number xx.

The Manager, Ethics Administration, University of Sydney:

- Telephone: +61 2 8627 8176
- Email: [human.ethics@sydney.edu.au](mailto:human.ethics@sydney.edu.au)
- Fax: +61 2 8627 8177 (Facsimile)

**(14) Has this study received funding?**

The study is funded by an NHMRC Centre Research Excellence Grant (2006545, CIA McCaffery) and an NHMRC Investigator Grant (1174523, CIA Bell)

## Pre-Survey Consent Form ✓

Do you consent to take part in this study as described in the Participant Information Sheet and Consent Form?

- ☐ Yes
- ☐ No

## Section 1: Screening and Socio-Demographic ✓

Which of the following best describes your current gender identity?

- ☐ Male
- ☐ Female
- ☐ Non-binary / gender fluid
- ☐ Different identity

Have you been previously diagnosed with a melanoma?

- ☐ Yes
- ☐ No

Do you have a partner?

- ☐ Spouse

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- ☐ De-facto partner
- ☐ Partner who does not reside with you
- ☐ No partner
- ☐ Widowed
- ☐ Divorced or separated
- ☐  Other - please list:

What is your age?

Section 1.5: Screening and Socio-Demographic Part 2

Which Australian state or territory do you currently live in?

- ☐ New South Wales
- ☐ Victoria
- ☐ Australian Capital Territory
- ☐ Queensland
- ☐ South Australia
- ☐ Western Australia
- ☐ Northern Territory
- ☐ Tasmania

Where are you located? (please enter your post code)

What is your highest level of education?

- ☐ Year 10 or below
- ☐ Year 11
- ☐ Year 12
- ☐ Certificate I/II
- ☐ Certificate III/IV
- ☐ Advanced diploma/diploma
- ☐ Bachelor's degree
- ☐ Graduate diploma/graduate certificate
- ☐ Postgraduate degree (Master's or Doctorate)
- ☐ Level not determined

What is your current employment status?

- ☐ Permanent or ongoing
- ☐ Fixed-term contract
- ☐ Casual/temporary (no paid sick leave or annual leave)
- ☐ Self-employed
- ☐ On paid leave (e.g. maternity leave)
- ☐ Unemployed
- ☐ Not working/not in the labour force (e.g. student, home duties, retired)

What was your total household income before taxes during the past 12 months?

- ☐ Less than AUD \$30,000
- ☐ Between AUD \$30,000 - \$49,999
- ☐ Between AUD \$50,000 - \$79,999
- ☐ Between AUD \$80,000 - \$99,999
- ☐ Between AUD \$100,000 - \$149,999
- ☐ Between AUD \$150,000 - \$199,999
- ☐ AUD \$200,000 or more
- ☐ Prefer not to say

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Do you have children?

- ☐ Yes
- ☐ No
- ☐ Prefer not to say


Are you of Aboriginal or Torres Strait Islander origin?

- ☐ Aboriginal
- ☐ Torres Strait Islander
- ☐ Both Aboriginal and Torres Strait Islander
- ☐ Neither Aboriginal or Torres Strait Islander
- ☐ Prefer not to say

What was your natural hair colour when you were 18 years of age

- ☐ Black
- ☐ Brown
- ☐ Fair or Blond
- ☐ Red or Auburn

Looking at the image below, please select the option that most closely resembles the number of moles on your body when you were 18 years of age.

**None****Few  
moles****Some  
moles****Many  
moles**

- ☐ None
- ☐ Few moles
- ☐ Some moles
- ☐ Many moles

Have you ever used a sunbed or sunlamp?

- ☐ No
- ☐ Yes

Were you born in Australia?

- ☐ Yes
- ☐ No

What is your country of birth?

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- ☐ UK
- ☐ India
- ☐ China
- ☐ New Zealand
- ☐ The Philippines
- ☐  Other - please list:

In which year did you move to Australia?

What language do you mostly speak at home?

- ☐ English
- ☐ Mandarin
- ☐ Arabic
- ☐ Cantonese
- ☐ Vietnamese
- ☐  Other - please list:

Do you have private health insurance?

- ☐ Yes
- ☐ No
- ☐ Don't know

Section 2: General Health ✓

In general, would you say your health is ...

- ☐ Excellent
- ☐ Very good
- ☐ Good
- ☐ Fair
- ☐ Poor

Have you ever been diagnosed with cancer?

- ☐ Yes
- ☐ No
- ☐ Don't know

Which type of cancer?

- ☐ Melanoma
- ☐ Skin (not melanoma)
- ☐ Prostate
- ☐ Breast
- ☐ Bowel
- ☐ Lung
- ☐ Lymphoma
- ☐  Other - please list:
- ☐ Don't know

Has a current or former partner ever been diagnosed with cancer?

- ☐ Yes
- ☐ No

1 Which type of cancer?  
2

- 3 ☐ Melanoma  
4  
5 ☐ Skin (not melanoma)  
6  
7 ☐ Prostate  
8  
9 ☐ Breast  
10  
11 ☐ Bowel  
12  
13 ☐ Lung  
14  
15 ☐ Lymphoma  
16  
17 ☐  Other - please list:  
18  
19 ☐ Don't know  
20  
21  
22  
23

24  
25 Has anyone in your immediate family (parents, siblings or children) ever been  
26 diagnosed with cancer?  
27

- 28  
29 ☐ Yes  
30  
31 ☐ No  
32  
33 ☐ Don't know  
34  
35  
36  
37

38  
39 Which type of cancer? Please tick all that apply  
40

- 41 ☐ melanoma  
42  
43 ☐ Skin (not melanoma)  
44  
45 ☐ Prostate  
46  
47 ☐ Breast  
48  
49 ☐ Bowel  
50  
51 ☐ Lung  
52  
53 ☐ Lymphoma  
54  
55 ☐  Other - please list:  
56  
57 ☐ Don't know  
58  
59  
60

Who was this? Please tick all that apply

- ☐ Mother
- ☐ Father
- ☐ Sister
- ☐ Brother
- ☐ Daughter
- ☐ Son
- ☐  Other - please list:

How worried are you about developing melanoma?

- ☐ Not worried at all
- ☐ A bit worried
- ☐ Quite worried
- ☐ Very worried

Sometimes, medical action is clearly necessary and sometimes it is clearly not necessary. Other times, reasonable people differ in their beliefs about whether medical action is needed.

In situations where it's not clear, do you tend to lean towards taking action or do you prefer to wait and see if action is needed?

Importantly, there is no right way to be.

- |                                       |                              |                                       |  |                               |  |
|---------------------------------------|------------------------------|---------------------------------------|--|-------------------------------|--|
| I strongly lean towards wait and see. | I lean towards wait and see. | I somewhat lean towards wait and see. | I somewhat lean towards taking action. | I lean towards taking action. | I strongly lean towards taking action. |
| <input type="radio"/>                 | <input type="radio"/>        | <input type="radio"/>                 | <input type="radio"/>                  | <input type="radio"/>         | <input type="radio"/>                  |

The following questions are related to how you have been feeling over the past two weeks. Please read each statement and then choose the most appropriate

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

option regarding how you felt in the last two weeks.

			Less than half of the time	More than half of the time	Most of the time	All of the time
	At no time	Some of the time				
I have felt cheerful and in good spirits.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I have felt calm and relaxed.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I have felt active and vigorous.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I woke up feeling fresh and rested.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
My daily life has been filled with things that interest me.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please respond to the following statements.

	Not at all true	Hardly true	Moderately true	Exactly true
I can always manage to solve difficult problems if I try hard enough.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
If someone opposes me, I can find the means and ways to get what I want.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
It is easy for me to stick to my aims and accomplish my goals.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I am confident that I could deal efficiently with unexpected events.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Not at all true      Hardly true      Moderately true      Exactly true

Thanks to my resourcefulness, I know how to handle unforeseen situations.

☐☐☐☐

I can solve most problems if I invest the necessary effort.

☐☐☐☐

I can remain calm when facing difficulties because I can rely on my coping abilities.

☐☐☐☐

When I am confronted with a problem, I can usually find several solutions.

☐☐☐☐

If I am in trouble, I can usually think of a solution.

☐☐☐☐

I can usually handle whatever comes my way.

☐☐☐☐

### Section 3: Health Literacy ✓

How often do you need to have someone help you when you read instructions, pamphlets or other written material from your doctor or pharmacy?

☐ Always

☐ Often

☐ Sometimes

☐ Occasionally

☐ Never

1  
2  
3 **Hypothetical - Control**  
4  
5  
6  
7

8 Please read the hypothetical information below and answer the questions that  
9 follow. You are asked to imagine as if the following information is true. Please  
10 answer how you would feel or react if you were in this situation, to the best of  
11 your ability.  
12  
13  
14

15  
16  
17  
18 You are at the doctor (GP) after you recently had a small surgery done to  
19 remove one of your moles.  
20  
21  
22

23 The doctor has the test results and says: "We found a melanoma in situ. We  
24 removed it all, with at least 3mm of normal skin around the melanoma in situ.  
25 You can decide whether or not you want us to remove more normal skin from  
26 around the scar. And you can also decide whether you would like to book in for  
27 regular skin checks with me every 6 months, or whether you would like us to  
28 teach you how to check your skin yourself and only book in to see us if you're  
29 worried about another mole. I recommend any of these options as a reasonable  
30 choice, and I will organise which ever ones you prefer."  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 **Hypothetical - Label 1**  
42  
43  
44

45 Please read the information below and answer the questions that follow. Please  
46 note that you will be asked to imagine as if the following information is true.  
47 Please answer how you would feel or react if you were in this situation, to the  
48 best of your ability.  
49  
50  
51  
52  
53  
54

55 You are at the doctor (GP) after you recently had a small surgery done to  
56 remove one of your moles.  
57  
58  
59  
60

The doctor has the test results and says: "We found a low risk melanocytic neoplasm. We removed it all, with at least 3mm of normal skin around the low risk melanocytic neoplasm. You can decide whether or not you want us to remove more normal skin from around the scar. And you can also decide whether you would like to book in for regular skin checks with me every 6 months, or whether you would like us to teach you how to check your skin yourself and only book in to see us if you're worried about another mole. I recommend any of these options as a reasonable choice, and I will organise which ever ones you prefer."

## Hypothetical - Label 2

Please read the information below and answer the questions that follow. Please note that you will be asked to imagine as if the following information is true. Please answer how you would feel or react if you were in this situation, to the best of your ability.

You are at the doctor (GP) after you recently had a small surgery done to remove one of your moles.

The doctor has the test results and says: "We found a low-risk melanocytic neoplasm, in situ. We removed it all, with at least 3mm of normal skin around the low-risk melanocytic neoplasm, in situ. You can decide whether or not you want us to remove more normal skin from around the scar. And you can also decide whether you would like to book in for regular skin checks with me every 6 months, or whether you would like us to teach you how to check your skin yourself and only book in to see us if you're worried about another mole. I recommend any of these options as a reasonable choice, and I will organise which ever ones you prefer."

Section 5: Primary and Secondary Outcome Measures ✓

After learning of your pathology result, how anxious do you feel?

Not anxious at all

Extremely anxious

0

1

2

3

4

5

6

7

8

9

10

How anxious

After learning of your pathology result, what percentage risk do you think you have of developing an invasive melanoma in your lifetime?

Low risk

High risk

0

10

20

30

40

50

60

70

80

90

100

How anxious

After learning of your pathology result, what percentage risk do you think you have of dying from melanoma?

Low risk

High risk

0

10

20

30

40

50

60

70

80

90

100

How anxious

After learning of your pathology result, which of these surgery management options would you choose?

- ☐ No further surgery
- ☐ Further surgery to remove more skin around the scar (so that the distance from the margins to the melanoma in situ are greater than 5 mm)

Please tell us how you decided on that surgery management option. What were

the important factors that helped you decide? [This question is optional].

After making that surgery management choice, how anxious do you feel?

	Not anxious at all					Extremely anxious					
	0	1	2	3	4	5	6	7	8	9	10
How anxious											

After learning of your pathology result, which of these follow up management options would you choose?

- ☐ I do my own skin checks with help from my partner/friend/relative. I am taught how to examine my total body and am given a special imaging device that clips on my phone. I have access to videos and online support to help me do skin checks and to use the imaging device. I can take images of any moles that concern me and send these to a dermatologist. If they are also concerned, then I am booked into clinic with my doctor for a skin check.
- ☐ My doctor does my skin check at regular 6 monthly appointments

Please tell us how you decided on that follow up management option. What were the important factors that helped you decide? [This question is optional].

After making that follow up management choice, how anxious do you feel?

	Not anxious at all					Extremely anxious					
	0	1	2	3	4	5	6	7	8	9	10
How anxious											

## Section 6: Debrief Statement ✓

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

You were a participant in this study which aimed to investigate how people would react to different information provision on diagnosis of a low-risk prostate lesion results by the label given to the prostate lesion.

During the study, you were asked to imagine a hypothetical scenario in which you or your partner are given a diagnosis result after having gone to a routine screening. You were then asked to complete a series of survey questions.

You were randomised to receive one of three different hypothetical scenarios.

These three diagnosis scenarios were:

1. Diagnosis of a melanoma in situ.
2. Diagnosis of a low-risk melanocytic neoplasm.
3. Diagnosis of a low-risk melanocytic neoplasm, in situ.

The purpose of this study was to examine the impact of these different labels/diagnoses on preferred management strategy and psychological outcomes such as worry and health seeking intentions.

It is important to remember that this study was entirely hypothetical (made up). The study team does not have access to any of your medical history.

If you have any further questions regarding the study, feel free to contact Prof Katy Bell ([katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au))

For more information on melanoma and skin checks, please visit the following websites:

[Melanoma Institute Australia](#)

## Cancer Council - Melanoma

### Section 7: Feedback ✓

Thank you for your participation in the survey. Your time and contribution is greatly appreciated. If you are interested in the results of the study, the results and a lay summary of the results will be published at the following permanent web page: [Wiser Healthcare publications](#)

Powered by Qualtrics

# BMJ Open

## Impact of alternative diagnostic labels for melanoma in-situ on management choices and psychological outcomes: protocol for an online randomised study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-089558.R1
Article Type:	Protocol
Date Submitted by the Author:	31-Oct-2024
Complete List of Authors:	Wu, Zhuohan; The University of Sydney, Sydney School of Public Health, Faculty of Medicine and Health Nickel, Brooke; University of Sydney, Sydney School of Public Health, Faculty of Medicine and Health; Wiser Healthcare Research Collaboration boroumand, farzaneh; The University of Sydney Elder, David; Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine Ferguson, Peter M.; Melanoma Institute Australia; Royal Prince Alfred Hospital and NSW Health Pathology, Tissue Pathology and Diagnostic Oncology Scolyer, Richard; The University of Sydney O'Brien, Blake; Sullivan Nicolaides Pathology, Surgical Pathology Barnhill, Raymond; Paris Sciences and Lettres Research University, Department of Translational Research Adamson, Adewole S.; Austin, Department of Internal Medicine; The University of Texas at Austin Dell Medical School, van Akkooi, Alexander C.J.; Melanoma Institute Australia Emery, Jon; University of Melbourne, General Practice and Primary Care Academic Centre Parker, Lisa; University of Sydney Low, Donald; Cancer Voices New South Wales Low, Cynthia; Cancer Voices New South Wales Davies, Elspeth; Patient Researcher, Cambridge Liu, Sherrie; Health Consumers New South Wales Lewis, Stacey; Health Consumers New South Wales Spongberg-Ross, Bella; Health Consumers New South Wales Bell, Katy; The University of Sydney; Wiser Healthcare Research Collaboration
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Health policy, Dermatology
Keywords:	Dermatological tumours < DERMATOLOGY, Adverse events < THERAPEUTICS, Clinical Decision-Making, Surgical dermatology < DERMATOLOGY, Surgical pathology < PATHOLOGY, Patient-Centered Care



**Impact of alternative diagnostic labels for melanoma in-situ on management choices and psychological outcomes: protocol for an online randomised study.**

Zhuohan Wu<sup>1</sup>, Brooke Nickel<sup>1,2</sup>, Farzaneh Boroumand<sup>1,3</sup>, David Elder<sup>4</sup>, Peter Ferguson<sup>5,6</sup>, Richard A. Scolyer<sup>5,6,7,8</sup>, Blake O'Brien<sup>9</sup>, Raymond Barnhill<sup>10</sup>, Adewole S Adamson<sup>11</sup>, Alexander C.J. van Akkooi<sup>5,12</sup>, Jon Emery<sup>13</sup>, Lisa Parker<sup>7,8,14</sup>, Donald Low<sup>15</sup>, Cynthia Low<sup>15</sup>, Elspeth Davies<sup>16</sup>, Sherrie Liu<sup>17</sup>, Stacey Lewis<sup>17</sup>, Bella Spongberg-Ross<sup>17</sup>, Katy JL Bell<sup>1,2</sup>

<sup>1</sup>Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

<sup>2</sup>Wiser Healthcare Research Collaboration, Sydney, NSW, Australia

<sup>3</sup>School of Mathematical and Physical Sciences, Macquarie University, NSW, Australia

<sup>4</sup>Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia

<sup>5</sup>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

<sup>6</sup>Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia

<sup>7</sup>Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

<sup>8</sup>Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia

<sup>9</sup>Sullivan Nicolaides Pathology, Brisbane, QLD, Australia

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

23 <sup>10</sup> Department of Translational Research, Institut Curie, Paris Sciences and Lettres  
24 Research University, and Faculty of Medicine University of Paris Descartes, Paris,  
25 France  
26 <sup>11</sup>Department of Internal Medicine (Division of Dermatology), The University of  
27 Texas at Austin Dell Medical School, Austin, TX 78701, USA  
28 <sup>12</sup> Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology,  
29 <sup>13</sup> Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia  
30 <sup>14</sup>Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia  
31 <sup>15</sup> Cancer Voices New South Wales, NSW, Australia  
32 <sup>16</sup> Patient Advocate, Cambridge, UK  
33 <sup>17</sup> Health Consumers New South Wales, NSW, Australia  
34  
35 **Corresponding Author and guarantor:** Katy Bell [katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

## 36 Abstract

## 37 Introduction

38 A diagnosis of melanoma in-situ presents negligible risk to a person's lifespan or  
39 physical wellbeing, but existing terminology makes it difficult for patients to  
40 distinguish these from higher risk invasive melanomas. This study aims to explore  
41 whether using an alternative label for melanoma in situ may influence patients'  
42 management choices and anxiety levels.

## 43 Methods and Analysis

44 This study is a between-subjects randomised online experiment, using hypothetical  
45 scenarios. Following consent, eligible participants will be randomised 1:1:1 to three  
46 labels: "melanoma in situ" (control), "low-risk melanocytic neoplasm" (intervention  
47 1) and "low-risk melanocytic neoplasm, in situ" (intervention 2). The required sample  
48 size is 1668 people. The co-primary outcomes are (i) choice between no further  
49 surgery or further surgery to ensure clear histological margins greater than 0.5mm,  
50 and (ii) choice between patient initiated clinical follow up when needed (patient-led  
51 surveillance) and regular routinely scheduled clinical follow-up (clinician-led  
52 surveillance). Secondary outcomes include diagnosis anxiety, perceived risk of  
53 invasive melanoma and of dying from melanoma, and management choice anxiety  
54 (after surgery choice and follow-up choice). We will make pairwise comparisons  
55 across the three diagnostic label groups using regression models (univariable and  
56 multivariable).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399

1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

1437

1438

1439

1440

1441

1442

1443

1444

1445

1446

1447

1448

1449

1450

1451

1452

1453

1454

1455

1456

1457

1458

1459

1460

1461

1462

1463

1464

1465

1466

1467

1468

1469

1470

1471

1472

1473

1474

1475

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

1487

1488

For peer review only

management decisions, and the impact of providing detailed risk information  
(and whether this may modify diagnostic label effects)<sup>1</sup>. These are important  
areas for future research.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

81     **INTRODUCTION**

82     Melanoma incidence and mortality trajectories in Australia and other countries show a  
83     classic epidemiologic signature of overdiagnosis<sup>2</sup>: steeply increasing incidence curves  
84     coupled with flat mortality trends<sup>3-7</sup>. While aging populations may lead to a small real  
85     increase in melanoma incidence<sup>8</sup>, much of the increase is likely overdiagnosis<sup>3-7, 3-7</sup>.  
86     This appears to be largely driven by increased diagnosis of melanoma in situ<sup>3 5 9</sup>,  
87     which in Australia is now diagnosed over twice as frequently as invasive melanoma<sup>10</sup>.  
88     Similar findings have been found for melanoma in the US (diagnosed at least as  
89     frequently as invasive melanoma)<sup>4</sup> and Denmark (diagnosed over half as frequently as  
90     invasive melanoma)<sup>11</sup>.  
91  
92     Multiple evidence lines indicate that melanoma in situ is a risk factor for invasive  
93     melanoma rather than an obligate precursor<sup>4 10 12 13, 4 10 12 13</sup>. Overdiagnosis is partly  
94     driven by lowering the diagnostic threshold over the years, such that the same lesion  
95     that was called benign in the past, would now be labeled melanoma in situ<sup>13</sup>.  
96     Concerns about litigation may also be driving a tendency to interpret melanocytic  
97     lesions as a more severe diagnosis<sup>14</sup> particularly in partial biopsies or where the lesion  
98     extends to the surgical margins. Harms stemming from melanoma overdiagnosis  
99     include physical, psychosocial, and economic dimensions<sup>15</sup>. Physical harms can  
100    include overtreatment, repeat skin biopsies<sup>16</sup>, scarring<sup>16</sup>, pain, infection, and/or  
101    functional impairment. Psychological harms include anxiety and fear<sup>17 18</sup>, with many

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

patients perceiving they have a high risk of dying from melanoma, when their actual risk is much lower (and risk all-cause mortality is actually lower than the population average)<sup>19</sup>. These psychological harms can manifest as anxiety about being outdoors, fear of cancer recurrence, or guilt for past UV exposure causing melanoma<sup>6</sup>. Social harms include impacts of the diagnosis on loved ones, and on patients' social networks<sup>16</sup>. Economic harms include treatment costs for the immediate diagnosis, and for future long term clinical surveillance. These incur substantial financial costs to both the health system and patient (as out-of-pocket costs), as well as opportunity costs for both clinician time and patient time. There is also a possible denial of life insurance as the person is now identified as a cancer survivor by many insurance companies (3).

One possible solution is to consider a new label for melanoma in situ without the word "melanoma"<sup>13</sup>. This might help patients recognize the lower risk of this type of lesion<sup>19</sup>, and help to reduce the potential psychological harm. It may also pave the way for the de-escalation of treatment<sup>20</sup> and surveillance<sup>21-23</sup>. Evidence from other cancer contexts, including thyroid<sup>24</sup>, breast<sup>25</sup>, and prostate<sup>26</sup> lesions, suggests that new diagnostic labels may beneficially impact psychological outcomes and management decisions<sup>27</sup>. We seek to build on these findings by investigating the potential impacts of new labels for melanoma in situ. To ensure relevance of our findings to end-users, we will test alternative labels for melanoma in situ that were chosen by our co-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Investigators representing clinicians, patients, and the public. Alternative label(s) need to be acceptable to both patients and clinicians, and convey the low, but not zero, risk of future invasive melanoma. This study aims to explore whether using an alternative diagnostic label to communicate a hypothetical melanoma in situ diagnosis influences management choice and level of anxiety among Australian adults.

**METHODS AND ANALYSIS**

*Study design*

An online randomised study of Australian community members will be run, with participants randomised to receive one of three hypothetical scenarios about the diagnosis of a melanoma in situ. Each group will be presented with a different diagnostic label, and we will survey participants about their preferred choices of management for that diagnosis, their level of anxiety about that diagnosis and their level of anxiety about their management choices.

This study is a between-subjects randomised online experiment. Following consent, eligible participants will be randomised 1:1:1 to “melanoma in situ” (control), “low risk melanocytic neoplasm” (intervention label 1), and “low risk melanocytic neoplasm, in situ” (intervention label 2). The co-primary outcomes and secondary outcomes will be compared across randomised groups.

There will be an equal probability of being assigned to each of the 3 groups, and we expect approximately equal numbers per group. We will use Qualtrics survey

software to randomly allocate participants into groups, present the scenarios, survey questions and collect data on the outcomes<sup>28</sup>. Our participants flow diagram present a summary of the randomisation of participants into the allocated control and intervention arms (Figure 1).

### ***Eligibility criteria***

Participants will be eligible if they are: 40 years or older, understand written English, and reside in Australia. Participants will be excluded if they have a history of melanoma (invasive or in-situ).

### ***Recruitment and data collection.***

Participants will be recruited from the general Australian public through an independent social research company (Dynata), which has a panel of 600,000 participants whose demographic characteristics align closely with those of the national population. Dynata has a points system in which participants receive points after completing surveys. The points can then be used to redeem vouchers, cash, or other rewards. Stratified sampling will be used, with quotas in place for gender (50% male, 50% female or other), age (25% for each of: 40-29 years, 50-59 years, 60-69 years, 70 years or older, +/- 15% allowed for first three age groups and +/-30% for oldest age group)<sup>29</sup>, education (50% high school or less, 50% more than high school, +/-15% allowed), and State or Territory of residence (quotas proportionate to

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Australian population, +/-5% allowed: New South Wales 31.3%, Victoria 25.6%,  
Queensland 20.5%, South Australia 6.9%, Western Australia 10.9%, Tasmania 2.1%,  
Northern Territory 0.9%, and Australian Capital Territory 1.7% <sup>30</sup>).

Participants who agree to participate in the study will complete an online Qualtrics  
survey managed by the research team. Only eligible participants will proceed to the  
randomisation step. The survey will capture baseline data and characteristics of  
participants including socio-demographic details including their age, location, health  
literacy, and personal and family history of any cancer, and participant responses on  
outcome measures. The survey questions are presented in the Supplement.

All data will be collected via Qualtrics software and hosted on The University of  
Sydney secure server. Information will be de-identified and we will not be able to link  
the survey back to participants. The non-identifiable data will be downloaded for  
analysis and stored within The University of Sydney’s Research Data Store.

***Determination of alternative labels to be tested.***

We undertook a targeted literature search in September 2023 by retrieving forward  
and backward citation searches of four key papers on the topic<sup>6 13 27 31</sup>. We used the  
automated tool ‘Spider Cite’<sup>32</sup>) to identify records, and Covidence to screen title,  
abstract and full-texts<sup>33</sup>. Of 593 unique records retrieved, we screened the full text of  
27, and included 7 papers describing 9 alternative labels (see Box 1).

Using short online questionnaires implemented in Qualtrics<sup>28</sup>, we then ran three

rounds of surveys with the 9 international Clinician co-Investigators (with expertise in dermatopathology, dermatology, surgical oncology, primary care, and radiation oncology), and 6 Patient/Public co-Investigators (two with lived experience of a melanoma diagnosis and four without a history of melanoma) to determine choice of alternative labels. This resulted in the final choice of two alternative labels that we will test in the online survey: *low-risk melanocytic neoplasm* and *low-risk melanocytic neoplasm, in situ*.

### ***Interventions***

Participants will be randomised using Qualtrics randomisation software to receive one of three hypothetical scenarios. They will not be blinded. In each scenario, the participant will be told that the results of their recent skin surgery indicates a particular diagnosis. Group 1 (the control group) will be told they have a *melanoma in situ*. Group 2 will be told they have a *low-risk melanocytic neoplasm*. Group 3 will be told they have a *low-risk melanocytic neoplasm, in situ*. We will not provide further explanation of what low-risk means.

### ***Primary and Secondary Outcomes***

Primary and secondary outcomes are described in Table 1. The co-primary outcomes are (i) participant's choice of surgical management option: no further surgery vs further surgery (to achieve pathology margins greater than 5mm), and (ii) follow-up

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

207 management option: patient led surveillance (self-skin examination with patient-  
208 initiated clinic visits) vs clinician led surveillance (six monthly routinely scheduled  
209 clinic visits).

210 The first co-primary outcome on surgical management choice reflects recent  
211 retrospective analyses that have found that narrower margins are likely to be as safe as  
212 margins currently recommended in guidelines in small melanoma in situ<sup>34</sup>. Indeed  
213 very narrow histological clearance ( $\geq 1$ mm) appears to be safe for melanoma in situ of  
214 the trunk and limbs<sup>35</sup>. The new MPATH-Dx V2.0 melanocytic lesion classification  
215 scheme recommends that provided margins are not involved, clinicians may consider  
216 not re-excising class II lesions – which includes melanoma in-situ<sup>36</sup>. The second co-  
217 primary outcome on follow-up management choice centres around patient-led  
218 surveillance (also called patient-initiated follow-up) as an alternative model of follow-  
219 up for cancer survivors to routinely scheduled clinic appointments<sup>37</sup>. Among people  
220 diagnosed and treated for early stage melanoma, patient-led surveillance is being  
221 evaluated in the MEL-SELF randomized controlled trial. Here, this model of care  
222 includes: training in self-skin examination, digital technologies to record and take  
223 images of concerning lesions (using a mobile dermatoscope), online system for  
224 submitting images for remote review by a dermatologist, and advice on whether  
225 urgent clinical review may be needed (teledermatology)<sup>38</sup>.

226 Secondary outcomes are: diagnosis anxiety, perceived lifetime risk of invasive  
227 melanoma, perceived lifetime risk of dying from melanoma, management choice

anxiety, and open-text explanation of management choices (free text input).

229

### *Sample size*

We estimated a sample size of 1668 participants with 556 participants per group in the study, which would provide 80% power ( $1 - \beta$ ) to detect a pairwise difference in the proportion of choosing no further surgery, and 89% power to detect a pairwise difference in the proportion in choosing patient-led surveillance as small as 10%.

The assumptions are: 50% would choose no further surgery (most conservative assumption) and 35%<sup>23</sup> would choose patient-led surveillance in the control label condition, a 5% dropout rate,  $\alpha = 0.05$ , the normal approximation to the binomial distribution, and the standard formula for comparing proportions in independent equal-sized groups.

### *Analysis*

The analysis will focus on assessing the impact of different diagnostic labels for melanoma in situ on participants' psychological responses and healthcare decisions.

Data analysts will be blinded to intervention assignment. For both co-primary outcomes, we will compare the proportion chosen for each management option. For first four secondary outcomes, we will compare summary statistical measures (means or medians) across randomised groups. For the last outcome, we will use thematic framework methods of qualitative data.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

249  
  
250  
  
251  
  
252  
  
253  
  
254  
  
255  
  
256  
  
257  
  
258  
  
259  
  
260  
  
261  
  
262  
  
263  
  
264  
  
265  
  
266  
  
267  
  
268  
  
269

The analysis will adhere to the intention-to-treat principle, and participant data will be analyzed according to their randomly assigned diagnostic label group, regardless of adherence to the study protocol. The number of participant responses included in each analysis will be presented for each outcome. We will summarize categorical data for the randomised groups using counts and percentages, and continuous data using the minimum and maximum, mean, and standard deviation (SD) or median and interquartile range (IQR).

Statistical analyses will be conducted within a superiority framework to make pairwise comparisons across the three diagnostic label groups. Binary outcomes will be analyzed using logistic regression. Continuous outcomes will be analyzed using linear regression. For the cancer worry outcome, we will compare changes in worry across randomised groups by including baseline scores as a covariate in the regression model. Effect estimates for all primary and secondary outcomes will be presented with associated 95% confidence intervals (CI). All hypothesis tests will be two-sided with a significance level ( $\alpha$ ) of 5%. The potential for participants' health literacy to act as an effect modifier of intervention effects will be explored.

We will estimate unadjusted and adjusted effects using the relevant regression model. These will include variables used in sampling strata: age, education, geographic

location (by state/territory). Prognostic factors will be measured through the baseline questionnaire, and include baseline anxiety levels, sun exposure behavior, prior diagnosis of melanoma, diagnosis of melanoma in a family member. The effects of participants' health literacy on intervention effects will also be explored as a potential confounder.

#### ***Planned start and end dates for the study***

The anticipated date of first participant enrolment was 01 July 2024 and the anticipated date of last data collection completion was 01 August 2024 (see Australian New Zealand Clinical Trials Registry entry ID 386943)

#### ***Patient and public involvement***

Two authors have lived experience of a melanoma diagnosis (one had MIS and one had a thin stage I invasive melanoma), and four authors are members of the public.

Two authors are affiliated with Cancer Voices NSW, one author is a patient researcher from Cambridge UK, and three authors are affiliated with Health Consumers NSW.

#### **Ethics and Dissemination**

Ethics approval of this project was provided by the University of Sydney on 06 May 2024 (No. 2024/HE000019). The study is registered with the Australian New Zealand Clinical Trials Registry (ID 386943). Updates to the protocol will be uploaded to the registry and identified by version number.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

As this study is an online randomised experiment which includes a hypothetical scenario, we do not anticipate significant adverse events because of the trial interventions or conduct. Participants are reminded at several points before and after the study as part of the participant information, consent and debrief processes that the nature of the study is hypothetical, that none of the information relates to their actual health or wellbeing, and that researchers do not have access to their actual medical histories or information. The debriefing content also includes links to relevant resources for participants who wish to find out more.

**Data availability statement**

The research team will have access to the final dataset. Access may be granted to other researchers on reasonable request. No contractual agreements limit the disclosure of data to other investigators. The findings of the study will be published in a peer-reviewed medical journal. A lay summary of the findings will be published via permanent link at the Wiser Healthcare publications page.

**Contributors**

ZW co-led drafting of the manuscript, led drafting of the study questionnaire and application to the Human Research Ethics Committee, and assisted with the targeted literature review (full text screening and data extraction). BN and KB conceptualized the research, provided methodological expertise. KB, who is the guarantor, led the targeted literature review and the Clinician and Consumer Investigator survey to decide the choice of alternative labels, and co-led drafting of the manuscript. FB

calculated the sample size. BN, FB DE, PF, RS, BO, RB, AAd, AAk, JE, LP, DL, CL, ED, SLi, SLe, BSR and KB revised the manuscript. All authors read, contributed to, and approved the final manuscript.

## **Funding**

National Health and Medical Research Council of Australia (NHMRC) Centre for Research Excellence Grant (2021/GNT2006545)

Brooke Nickel: NHMRC Investigator Grant (2020/GNT1113532)

RAS: NHMRC Investigator Grant (2022/GNT2018514)

Katy Bell: NHMRC Investigator Grant (2019/GNT1174523)

## **Declaration of Interests**

RAS has received fees for professional services from SkylineDx BV, IO Biotech ApS,

MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus

Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare,

AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline.

AvA received Advisory Board/Consultancy Honoraria from 4SC AG, Amgen,

Bristol-Myers Squibb, Merck Serono-Pfizer, MSD-Merck, Neracare, Novartis, Pierre

Fabre, Sanofi, Sirius Medical, SkylineDX and Research Grants from Amgen, Merck

Serono-Pfizer, SkylineDX.

All other authors have no conflicts of interest to declare.

**References:**

1. Bullen J, Nickel B, McCaffery K, et al. Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experiments. *BMJ Open* 2024;14(8):e085947. doi: 10.1136/bmjopen-2024-085947 [published Online First: 20240809]

2. Welch HG, Kramer Barnett S, Black William C. Epidemiologic Signatures in Cancer. *New England Journal of Medicine* 2019;381(14):1378-86. doi: 10.1056/NEJMSr1905447

3. Glasziou PP, Jones MA, Pathirana T, et al. Estimating the magnitude of cancer overdiagnosis in Australia. *Med J Aust* 2020;212(4):163-68. doi: 10.5694/mja2.50455 [published Online First: 2019/12/21]

4. Welch HG, Mazer BL, Adamson AS. The Rapid Rise in Cutaneous Melanoma Diagnoses. *N Engl J Med* 2021;384(1):72-79. doi: 10.1056/NEJMSb2019760 [published Online First: 2021/01/07]

5. Adewole SA, Geetanjali N, Mark AJ, et al. Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method. *BMJ Evidence-Based Medicine* 2024:bmjebm-2023-112460. doi: 10.1136/bmjebm-2023-112460

6. Adamson AS, Suarez EA, Welch HG. Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. *JAMA Dermatology* 2022;158(4):426-31. doi: 10.1001/jamadermatol.2022.0139

7. Mille Falk B, Emma Grundtvig G, John Brandt B. Overdiagnosis in malignant melanoma: a scoping review. *BMJ Evidence-Based Medicine* 2024;29(1):17. doi: 10.1136/bmjebm-2023-112341
8. Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. *The Lancet* 2023;402(10400):485-502. doi: 10.1016/S0140-6736(23)00821-8
9. Whiteman DC, Olsen CM, MacGregor S, et al. The effect of screening on melanoma incidence and biopsy rates. *Br J Dermatol* 2022;187(4):515-22. doi: 10.1111/bjd.21649 [published Online First: 2022/05/10]
10. Olsen CM, Pandeya N, Rosenberg PS, et al. Incidence of in Situ vs Invasive Melanoma: Testing the "Obligate Precursor" Hypothesis. *J Natl Cancer Inst* 2022;114(10):1364-70. doi: 10.1093/jnci/djac138 [published Online First: 2022/09/01]
11. Nielsen JB, Kristiansen IS, Thapa S. Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold? *British Journal of Dermatology* 2024;ljae175. doi: 10.1093/bjd/ljae175
12. Elder DE. Obligate and Potential Precursors of Melanoma. *JNCI: Journal of the National Cancer Institute* 2022;114(10):1320-22. doi: 10.1093/jnci/djac139
13. Semsarian CR, Ma T, Nickel B, et al. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? *British Journal of Dermatology* 2022;186(6):1030-32. doi: 10.1111/bjd.21010

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

374 14. Titus LJ, Reisch LM, Tosteson ANA, et al. Malpractice Concerns, Defensive  
375 Medicine, and the Histopathology Diagnosis of Melanocytic Skin Lesions. *Am J Clin*  
376 *Pathol* 2018;150(4):338-45. doi: 10.1093/ajcp/aqy057 [published Online First:  
377 2018/07/15]

378 15. Bell KJL, Nijsten T. Melanoma overdiagnosis: why it matters and what can be  
379 done about it. *Br J Dermatol* 2022;187(4):459-60. doi: 10.1111/bjd.21750 [published  
380 Online First: 2022/08/06]

381 16. Elspeth D. Informed by research, transformed by research. *BMJ Evidence-Based*  
382 *Medicine* 2024;29(1):62. doi: 10.1136/bmjebm-2023-112646

383 17. Bell KJL, Mehta Y, Turner RM, et al. Fear of new or recurrent melanoma after  
384 treatment for localised melanoma. *Psycho-Oncology* 2017;26(11):1784-91. doi:  
385 <https://doi.org/10.1002/pon.4366>

386 18. Mahama AN, Haller CN, Labrada J, et al. Lived Experiences and Fear of Cancer  
387 Recurrence Among Survivors of Localized Cutaneous Melanoma. *JAMA Dermatol*  
388 2024;160(5):495-501. doi: 10.1001/jamadermatol.2023.6158 [published Online First:  
389 2024/02/14]

390 19. Patel VR, Roberson ML, Pignone MP, et al. Risk of Mortality After a Diagnosis  
391 of Melanoma In Situ. *JAMA Dermatology* 2023;159(7):703-10. doi:  
392 10.1001/jamadermatol.2023.1494

20. Zijlker LP, Eggermont AMM, van Akkooi ACJ. The end of wide local excision (WLE) margins for melanoma ? *European Journal of Cancer* 2023;178:82-87. doi: <https://doi.org/10.1016/j.ejca.2022.10.028>
21. Moncrieff MD, Bastiaannet E, Underwood B, et al. Follow-up Schedule for Patients With Sentinel Node–negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial. *Annals of Surgery* 2022;276(4):e208-e16.
22. Lim W-Y, Morton RL, Turner RM, et al. Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma. *JAMA Dermatology* 2018;154(4):420-27. doi: 10.1001/jamadermatol.2018.0021
23. Drabarek D, Ackermann D, Medcalf E, et al. Acceptability of a Hypothetical Reduction in Routinely Scheduled Clinic Visits Among Patients With History of a Localized Melanoma (MEL-SELF): Pilot Randomized Clinical Trial. *JMIR Dermatol* 2023;6:e45865. doi: 10.2196/45865
24. Nickel B, Barratt A, McGeechan K, et al. Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized Crossover Trial. *JAMA Otolaryngol Head Neck Surg* 2018;144(10):867-74. doi: 10.1001/jamaoto.2018.1272 [published Online First: 2018/10/20]
25. McCaffery K, Nickel B, Moynihan R, et al. How different terminology for ductal carcinoma in situ impacts women's concern and treatment preferences: a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

413 randomised comparison within a national community survey. BMJ Open  
414 2015;5(11):e008094. doi: 10.1136/bmjopen-2015-008094

415 26. Berlin A, Ramotar M, Santiago AT, et al. The influence of the “cancer” label on  
416 perceptions and management decisions for low-grade prostate cancer. JNCI: Journal  
417 of the National Cancer Institute 2023;115(11):1364-73. doi: 10.1093/jnci/djad108

418 27. Nickel B, Moynihan R, Barratt A, et al. Renaming low risk conditions labelled as  
419 cancer. Bmj 2018;362:k3322. doi: 10.1136/bmj.k3322 [published Online First:  
420 2018/08/14]

421 28. Qualtrics. Qualtrics 2024 [Available from: <https://www.qualtrics.com/>.

422 29. Australian Bureau of Statistics (ABS). Regional population by age and sex 2023  
423 [Available from: [https://www.abs.gov.au/statistics/people/population/regional-](https://www.abs.gov.au/statistics/people/population/regional-population-age-and-sex/latest-release)  
424 [population-age-and-sex/latest-release](https://www.abs.gov.au/statistics/people/population/regional-population-age-and-sex/latest-release) accessed 15 October 2024.

425 30. Australian Bureau of Statistics (ABS). National, state and territory population  
426 2023 [Available from: [https://www.abs.gov.au/statistics/people/population/national-](https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2023)  
427 [state-and-territory-population/dec-2023](https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2023) accessed 15 October 2024.

428 31. Elmore JG, Barnhill RL, Elder DE, et al. Pathologists' diagnosis of invasive  
429 melanoma and melanocytic proliferations: observer accuracy and reproducibility  
430 study. BMJ 2017;357:j2813. doi: 10.1136/bmj.j2813 [published Online First:  
431 20170628]

32. Clark J, Glasziou P, Del Mar C, et al. A full systematic review was completed in 2 weeks using automation tools: a case study. *J Clin Epidemiol* 2020;121:81-90. doi: 10.1016/j.jclinepi.2020.01.008 [published Online First: 20200128]
33. Veritas Health Innovation. Covidence systematic review software [Available from: [www.covidence.org](http://www.covidence.org).
34. Sun C, Lim A, De'Ambrosio B, et al. Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin. *JAMA Dermatology* 2024;160(8) doi: 10.1001/jamadermatol.2024.1878
35. Smith H, Hussain W. Is it time we changed the way we manage melanoma in situ of the trunk and limbs? *British Journal of Dermatology* 2023;188(5):685-87. doi: 10.1093/bjd/ljad031
36. Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement. *JAMA Netw Open* 2023;6(1):e2250613. doi: 10.1001/jamanetworkopen.2022.50613 [published Online First: 20230103]
37. Dretzke J, Chaudri T, Balaji R, et al. A systematic review of the effectiveness of patient-initiated follow-up after cancer. *Cancer Medicine* 2023;12(18):19057-71. doi: <https://doi.org/10.1002/cam4.6462>
38. Ackermann DM, Dieng M, Medcalf E, et al. Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

453 Randomized Clinical Trial. JAMA Dermatology 2022;158(1):33-42. doi:  
454 10.1001/jamadermatol.2021.4704

455 39. Vuong K, Armstrong BK, Weiderpass E, et al. Development and External  
456 Validation of a Melanoma Risk Prediction Model Based on Self-assessed Risk  
457 Factors. JAMA Dermatology 2016;152(8):889-96. doi:  
458 10.1001/jamadermatol.2016.0939

459 40. World Health Organization. Wellbeing measures in primary health care/the  
460 DepCare Project: report on a WHO meeting: Stockholm, Sweden, 12–13 February  
461 1998: World Health Organization. Regional Office for Europe, 1998.

462 41. Scherer LD, Zikmund-Fisher BJ. Eliciting medical maximizing-minimizing  
463 preferences with a single question: development and validation of the MM1. Medical  
464 Decision Making 2020;40(4):545-50.

465 42. Morris NS, MacLean CD, Chew LD, et al. The Single Item Literacy Screener:  
466 evaluation of a brief instrument to identify limited reading ability. BMC family  
467 practice 2006;7:1-7.

468 43. Schwarzer R, Jerusalem M. Generalized self-efficacy scale. J Weinman, S Wright,  
469 & M Johnston, Measures in health psychology: A user's portfolio Causal and control  
470 beliefs 1995;35:37.

471 44. Davey HM, Barratt AL, Butow PN, et al. A one-item question with a Likert or  
472 Visual Analog Scale adequately measured current anxiety. Journal of clinical  
473 epidemiology 2007;60(4):356-60.

- 1  
2  
3  
4 474 45. Dillard AJ, Ferrer RA, Welch JD. Associations between narrative transportation,  
5  
6 475 risk perception and behaviour intentions following narrative messages about skin  
7  
8  
9 476 cancer. *Psychology & Health* 2017;33(5):573-93. doi:  
10  
11  
12 477 10.1080/08870446.2017.1380811  
13  
14 478  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

**Box 1: Process to select alternative labels to melanoma in situ for testing**

- In the first-round surveys Clinician and Patient/Public co-Investigators indicated their ranking the 7 labels identified in the targeted literature search, and 2 additional labels in order of preference. The potential alternative labels from the literature search were: Melanocytic neoplasm of low malignant potential (8,24,25), Melanocytic neoplasm, Atypical neoplasm" (25), Severe or High-Grade Melanocytic Dysplasia, Superficial Atypical Melanocytic Proliferation of Uncertain Malignant Significance (SAMPUS) (26–28), Melanocytic Tumor of Uncertain Malignant Potential (MELTUMP), Melanocytoma (28). The two additional labels suggested by the research team were: low-risk melanocytic neoplasm and low-risk melanocytic lesion.
- In the second round surveys, co-Investigators indicated their preferred ranking of the top three choices from round 1 and two new labels suggested in round 1: Low-risk melanocytic neoplasm, Low-risk melanocytic lesion, and Melanocytic neoplasm of low malignant potential, Melanocytic intraepithelial neoplasia, and In situ melanocytic neoplasm.
- In the third round surveys, co-Investigators indicated their preferred ranking of the top two choices from round 2, and three new labels suggested in round 2: In situ melanocytic neoplasm, Low-risk melanocytic neoplasm, In situ melanocytic neoplasm, low risk, low-risk melanocytic neoplasm, in-situ, and dysplastic naevus. The two highest ranked labels, chosen as the alternative labels to test in the online

experiment, were: “*low-risk melanocytic neoplasm*” and “*low-risk melanocytic neoplasm, in-situ*”.

479

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

480 **Table 1. Participant characteristics and outcome measures.**

Variable	Measure
Participant Characteristics	
Melanoma risk	Melanoma risk prediction based self-assessed risk factors <sup>39</sup>
General mood and wellbeing.	WHO (Five) Well-Being Questionnaire. <sup>40</sup>
Medical minimiser/maximiser.	Single-Item Maximiser/Minimiser Elicitation Question (MM1). <sup>41</sup>
Health literacy.	Single Item Literacy Screener (SILS). <sup>42</sup>
Melanoma worry.	Direct choice between specified options, one choice possible.
Self-efficacy.	Generalized Self-Efficacy Scale (GSE). <sup>43</sup>
Primary Outcomes	
Co-primary outcomes are choices for two management decisions. 1. Choice of further surgery: • No further surgery • Further surgery to ensure margins >0.5mm from lesion on pathology 2. Choice of follow-up: • Patient led surveillance: self-monitoring with patient-initiated clinic visits as needed • Clinician led surveillance: six monthly routinely scheduled clinic visits	Direct choice between two management approaches for each co-primary outcome Choice of further surgery and choice of follow-up.
Secondary Outcomes	
Diagnosis anxiety (feelings)	Single-question Visual Analogue Scale (0-6). <sup>44 45</sup>
Experiential perceived risk (vulnerability)	Single-question Visual Analogue Scale (0-6). <sup>45</sup>
Perceived lifetime absolute risk of invasive melanoma	Single-question Visual Analogue Scale (0-100). <sup>45</sup>
Perceived lifetime comparative risk of invasive melanoma	Single-question Visual Analogue Scale (0-6). <sup>45</sup>

Perceived lifetime risk of dying from melanoma	Single-question Visual Analogue Scale (0-100).
Management choice anxiety.	Single-question Visual Analogue Scale (0-6). <sup>44</sup>
Open-text explanation of management choice.	Free text (optional)

481

482

For peer review only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1.** Study Consolidated Standards of Reporting Trials flow diagram for participants. Participants' selection inclusion criteria are age over 40, understanding written English and residing in Australia. Patients will be excluded if they have melanoma, or do not provide consent.

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figure 1. Study CONSORT flow diagram



**Landing Page ✓**

**Does the label for a low-risk melanocytic lesion influence management choice: a randomised experiment.**

Thank you for your interest in our study about low-risk melanocytic lesions.

In this study, you will be randomised to be shown one of three hypothetical scenarios following surgery on a mole, which will be followed by questions about management options and anxiety.

The study is being conducted by a team of researchers from The University of Sydney School of Public Health. The team members are:

- Professor Katy Bell (School of Public Health at the University of Sydney)
- Dr Brooke Nickel (School of Public Health at the University of Sydney)
- Mr Zhuohan Wu (School of Public Health at the University of Sydney)

Taking part in the study involves completing one online questionnaire which will take approximately 10 minutes to complete.

Being in this study is completely voluntary and you do not have to take part. Your decision on whether to participate will not affect your current or future relationship with the researchers or anyone else at the University of Sydney.

Please take the time to read through the Participant Information Statement below.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

If you are interested in taking part in this study, you will be asked to consent to take part by ticking the 'yes' box at the beginning of the questionnaire. By giving your consent to take part in this study, you are telling us that you:

- ✓ Understand what you have read in the Participant Information Statement.
- ✓ Agree to take part in the research study as outlined in Participant Information Statement.
- ✓ Agree to the use of your personal information as described.

When you have consented, you will fill out an online questionnaire that asks a series of questions, such as:

- Demographic questions, such as age, education, income level and relationship status.
- General health and cancer related questions.
- Melanoma and other cancer history related questions.

You will be randomised to read one of three **HYPOTHETICAL EXAMPLES** (these are made-up examples) in which different labels are used to explain a low-risk melanocytic skin lesion result. **Please note that you WILL NOT be receiving information or advice on any real mole check results or information about your actual health status.**

The hypothetical examples will be followed by questions about choice of management strategy and personal perspective.

Note that there is no back button. Please give your best answer to each question before moving on to the next.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Pre-Survey PIS ✓

You can click the link below to download the Participants Information Sheet for more information about this study.

[Participants Information Sheet](#)

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Pre-Survey Consent Form ✓

Do you consent to take part in this study as described in the welcome page and Participants Information Sheet?

- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- ☐ Yes
- ☐ No

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Section 1: Screening and Socio-Demographic ✓

Have you been previously diagnosed with a melanoma?

- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- ☐ Yes
- ☐ No

What is your age?

47

48

49

50

51

52

53

54

55

56

57

58

59

60

53

54

55

56

57

58

59

60

Section 1.5: Screening and Socio-Demographic Part 2

Which of the following best describes your current gender identify?

- ☐ Male
- ☐ Female
- ☐ Non-binary / gender fluid
- ☐ Different identify

Which Australian state or territory do you currently live in?

- ☐ New South Wales
- ☐ Victoria
- ☐ Australian Capital Territory
- ☐ Queensland
- ☐ South Australia
- ☐ Western Australia
- ☐ Northern Territory
- ☐ Tasmania

Where are you located? (please enter your post code)

What is your highest level of education?

- ☐ Year 10 or below
- ☐ Year 11
- ☐ Year 12
- ☐ Certificate I/II
- ☐ Certificate III/IV
- ☐ Advanced diploma/diploma
- ☐ Bachelor's degree
- ☐ Graduate diploma/graduate certificate
- ☐ Postgraduate degree (Masters or Doctorate)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

☐  Other - please specify:

What is your current employment status?

- ☐ Permanent or ongoing
- ☐ Fixed-term contract
- ☐ Casual/temporary (no paid sick leave or annual leave)
- ☐ Self-employed
- ☐ On paid leave (e.g. maternity leave)
- ☐ Unemployed
- ☐ Not working/not in the labour force (e.g. student, home duties, retired)

What was your total household income before taxes during the past 12 months?

- ☐ Less than AUD \$30,000
- ☐ Between AUD \$30,000 - \$49,999
- ☐ Between AUD \$50,000 - \$79,999
- ☐ Between AUD \$80,000 - \$99,999
- ☐ Between AUD \$100,000 - \$149,999
- ☐ Between AUD \$150,000 - \$199,999
- ☐ AUD \$200,000 or more
- ☐ Prefer not to say

Do you have private health insurance?

- ☐ Yes
- ☐ No
- ☐ Don't know

## Do you have a partner?

- ☐ Spouse
- ☐ De-facto partner
- ☐ Partner who does not reside with you
- ☐ No partner
- ☐ Widowed
- ☐ Divorced or separated
- ☐  Other - please list:

## Do you have children?

- ☐ Yes
- ☐ No
- ☐ Prefer not to say

## Are you of Aboriginal or Torres Strait Islander origin?

- ☐ Aboriginal
- ☐ Torres Strait Islander
- ☐ Both Aboriginal and Torres Strait Islander
- ☐ Neither Aboriginal or Torres Strait Islander
- ☐ Prefer not to say

## Were you born in Australia?

- ☐ Yes
- ☐ No

1 What is your country of birth?  
2

- 3 ☐ UK  
4  
5 ☐ India  
6  
7 ☐ China  
8  
9 ☐ New Zealand  
10  
11 ☐ The Philippines  
12  
13 ☐  Other - please list:  
14  
15  
16  
17  
18

19 In which year did you move to Australia?  
20

21   
22  
23  
24  
25


26 What language do you mostly speak at home?  
27

- 28 ☐ English  
29  
30 ☐ Mandarin  
31  
32 ☐ Arabic  
33  
34 ☐ Cantonese  
35  
36 ☐ Vietnamese  
37  
38 ☐  Other - please list:  
39  
40  
41  
42  
43

44 What was your natural hair colour when you were 18 years of age  
45

- 46 ☐ Black  
47  
48 ☐ Brown  
49  
50 ☐ Fair or Blond  
51  
52 ☐ Red or Auburn  
53  
54  
55  
56  
57  
58  
59  
60

Looking at the image below, please select the option that approximately represents the number of moles on your body when you were aged 18 years, as best as you can remember.



- ☐ None
- ☐ Few moles
- ☐ Some moles
- ☐ Many moles

Have you ever used a sunbed or sunlamp?

- ☐ Yes
- ☐ No

## Section 2: General Health Screening

Have you ever been diagnosed with any type of cancer?

- ☐ Yes
- ☐ No
- ☐ Don't know

## Which type of cancer?

- ☐ Melanoma
- ☐ Skin (not melanoma)
- ☐ Prostate
- ☐ Breast
- ☐ Bowel
- ☐ Lung
- ☐ Lymphoma
- ☐  Other - please list:
- ☐ Don't know

## Section 2: General Health ✓

In general, would you say your health is ...

- ☐ Excellent
- ☐ Very good
- ☐ Good
- ☐ Fair
- ☐ Poor

Has a current or former partner or a close friend ever been diagnosed with cancer?

- ☐ Yes

☐ No

Which type of cancer?

☐ Melanoma

☐ Skin (not melanoma)

☐ Prostate

☐ Breast

☐ Bowel

☐ Lung

☐ Lymphoma

☐  Other - please list:

☐ Don't know

Has anyone in your close family ever been diagnosed with cancer?

☐ Yes

☐ No

☐ Don't know

Which type of cancer? Please tick all that apply

☐ Melanoma

☐ Skin (not melanoma)

☐ Prostate

☐ Breast

☐ Bowel

☐ Lung

☐ Lymphoma

☐  Other - please list:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

☐ Don't know

Who was this? Please tick all that apply

- ☐ Mother
- ☐ Father
- ☐ Sister
- ☐ Brother
- ☐ Daughter
- ☐ Son
- ☐  Other - please list:

How worried are you about developing melanoma?

- ☐ Not worried at all
- ☐ A bit worried
- ☐ Quite worried
- ☐ Very worried

Sometimes, medical action is clearly necessary and sometimes it is clearly not necessary.

Other times, reasonable people differ in their beliefs about whether medical action is needed.

In situations where it's not clear, do you tend to lean towards taking action or do you prefer to wait and see if action is needed?

Importantly, there is no right way to be.

- ☐ I strongly lean towards wait and see.

- ☐ I lean towards wait and see.
- ☐ I somewhat lean towards wait and see.
- ☐ I somewhat lean towards taking action.
- ☐ I lean towards taking action.
- ☐ I strongly lean towards taking action.

The following questions are related to how you have been feeling over the past two weeks. Please read each statement and then choose the most appropriate option regarding how you felt in the last two weeks.

	At no time	Some of the time	Less than half of the time	More than half of the time	Most of the time	All of the time
I have felt cheerful and in good spirits.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I have felt calm and relaxed.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I have felt active and vigorous.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I woke up feeling fresh and rested.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
My daily life has been filled with things that interest me.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please respond to the following statements.

	Not at all true	Hardly true	Moderately true	Mostly true
I can always manage to solve difficult problems if I try hard enough.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
If someone opposes me, I can find the means and	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Not at all true	Hardly true	Moderately true	Mostly true
ways to get what I want.				
It is easy for me to stick to my aims and accomplish my goals.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I am confident that I could deal efficiently with unexpected events.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thanks to my resourcefulness, I know how to handle unforeseen situations.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
	Not at all true	Hardly true	Moderately true	Mostly true
I can solve most problems if I invest the necessary effort.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I can remain calm when facing difficulties because I can rely on my coping abilities.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
When I am confronted with a problem, I can usually find several solutions.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
If I am in trouble, I can usually think of a solution.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I can usually handle whatever comes my way.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Section 3: Health Literacy ✓

How often do you need to have someone help you when you read instructions, pamphlets or other written material from your doctor or pharmacy?

☐ Always

☐ Often

☐ Sometimes

☐ Occasionally

☐ Never

## Randomized hypothetical labels

Please read the hypothetical information below and answer the questions that follow. You are asked to imagine as if the following information is true. Please answer how you would feel or react if you were in this situation, to the best of your ability.

You are at the doctor (GP) after you recently had a small surgery done to remove one of your moles.

The doctor has the pathology test results and says: "We found a **{e://Field/Label}**. We removed it all, and also 3mm of normal skin around the **{e://Field/Label}**."

## Section 5: Primary and Secondary Outcome Measures ✓

**Given the diagnosis of {e://Field/Label}, how anxious do you feel?**

*Answer from Not at all anxious (0) to Extremely anxious(6).*

	Not at all			Extremely			
	0	1	2	3	4	5	6

**Given the diagnosis of {e://Field/Label}, how vulnerable do you feel to developing invasive melanoma sometime in your life?**


*Answer from Not at all vulnerable (0) to Extremely vulnerable (6).*

Not at all

Extremely

0123456

Given the diagnosis of  $\{e://Field/Label\}$ , on a scale of 0–100%, what do you think your chances are of **developing** an invasive melanoma sometime in your life?




Given the diagnosis of  $\{e://Field/Label\}$ , what do you think your chances are of developing an invasive melanoma, compared to others of your age, gender, and skin colour?

Answer from Much lower chance (0) to Much higher chance (6).



Given the diagnosis of  $\{e://Field/Label\}$ , on a scale of 0 –100%, what do you think your chances are of **dying** from melanoma?



Please explain your reasoning behind the percentage you provided. [This question is optional]

Your doctor continues: "You now need to decide whether you would like us to do further surgery to remove more normal skin from around the scar, or whether you would prefer no further surgery at this time. I recommend either of these options as a reasonable choice and will organise whichever you prefer."

**Given the diagnosis of \${e://Field/Label}, which of these surgery management options would you choose?**

- ☐ Further surgery to remove more normal skin around the scar (so that the distance from the margins to the \${e://Field/Label} is greater than 5 mm)
- ☐ No further surgery

Please tell us how you decided on that surgery management option. What were the important factors that helped you decide? [This question is optional].

After making that surgery management choice, how anxious do you feel?  
*Answer from Not at all anxious (0) to Extremely anxious (6).*

Not at all					Extremely	
0	1	2	3	4	5	6

Your doctor further explains that there are also different options for follow-up: "You need to also decide whether you would like to book in for regular skin checks with me every 6 months, or you would like us to teach you how to check your skin yourself (with tele-dermatologist support) and book in with me only if needed. Again, I recommend either option as a reasonable choice, and will organise whichever one you prefer."

Given the diagnosis of **{e://Field/Label}**, which of these follow-up management options would you choose?

- ☐ My doctor does my skin check at regular 6 monthly appointments.
- ☐ I do my own skin checks with help from my partner/friend/relative (to check my back and other hard to see areas), and book in with my doctor when I need to.
  - I am taught how to examine my total body and am given a special imaging device that clips on my phone.
  - I have access to videos and online support to help me do skin checks and use the imaging device.
  - I can take images of any moles that concern me and send these to a dermatologist.
  - If the dermatologist is concerned, then I am booked in immediately for a skin check with my doctor.

Please tell us how you decided on that follow up management option. What were the important factors that helped you decide? [This question is optional].

After making that follow up management choice, how anxious do you feel?  
*Answer from Not at all anxious (0) to Extremely anxious (6).*

Not at all			Extremely			
0	1	2	3	4	5	6

Section 6: Debrief Statement ✓

You were a participant in this study which aimed to investigate how people would react to different information provision on diagnosis of a low-risk melanocytic lesion results by the label given to the melanocytic lesion.

During the study, you were asked to imagine a hypothetical scenario in which you are given a diagnosis result after having gone to a routine screening. You

were then asked to complete a series of survey questions.

You were randomised to receive one of three different hypothetical scenarios.

These three diagnosis scenarios were:

1. Diagnosis of a melanoma in situ.
2. Diagnosis of a low-risk melanocytic neoplasm.
3. Diagnosis of a low-risk melanocytic neoplasm, in situ.

The purpose of this study was to examine the impact of these different labels/diagnoses on preferred management strategy and psychological outcomes such as worry and health seeking intentions.

It is important to remember that this study was entirely hypothetical (made up). The study team does not have access to any of your medical history.

If you have any further questions regarding the study, feel free to contact Prof Katy Bell ([katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au))

For more information on melanoma and skin checks, please visit the following websites:

[Melanoma Institute Australia](#)

[Cancer Council - Melanoma](#)

We are conducting a follow-up study to explore individuals' experiences, concerns, and preferences regarding current and potential alternative labels for melanoma in situ. Would you be interested in participating in an interview

over the telephone or using web conferencing tools like Zoom or Microsoft Teams?

- ☐ Yes
- ☐ No

Thank you for your interest! Please provide your email address below so we can contact you to schedule the interview.

Section 7: Feedback ✓

Thank you for your participation in the survey. Your time and contribution is greatly appreciated. If you are interested in the results of the study, the results and a lay summary of the results will be published at the following permanent web page: [Wiser Healthcare publications](#)

Powered by Qualtrics

BMJ Open: first published as 10.1136/bmjopen-2024-089558 on 20 December 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

# BMJ Open

## Impact of alternative diagnostic labels for melanoma in-situ on management choices and psychological outcomes: protocol for an online randomised study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-089558.R2
Article Type:	Protocol
Date Submitted by the Author:	18-Nov-2024
Complete List of Authors:	Wu, Zhuohan; The University of Sydney, Sydney School of Public Health, Faculty of Medicine and Health Nickel, Brooke; University of Sydney, Sydney School of Public Health, Faculty of Medicine and Health; Wiser Healthcare Research Collaboration boroumand, farzaneh; The University of Sydney Elder, David; Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine Ferguson, Peter M.; Melanoma Institute Australia; Royal Prince Alfred Hospital and NSW Health Pathology, Tissue Pathology and Diagnostic Oncology Scolyer, Richard; The University of Sydney O'Brien, Blake; Sullivan Nicolaides Pathology, Surgical Pathology Barnhill, Raymond; Paris Sciences and Lettres Research University, Department of Translational Research Adamson, Adewole S.; Austin, Department of Internal Medicine; The University of Texas at Austin Dell Medical School, van Akkooi, Alexander C.J.; Melanoma Institute Australia Emery, Jon; University of Melbourne, General Practice and Primary Care Academic Centre Parker, Lisa; University of Sydney Low, Donald; Cancer Voices New South Wales Low, Cynthia; Cancer Voices New South Wales Davies, Elspeth; Patient Researcher, Cambridge Liu, Sherrie; Health Consumers New South Wales Lewis, Stacey; Health Consumers New South Wales Spongberg-Ross, Bella; Health Consumers New South Wales Bell, Katy; The University of Sydney; Wiser Healthcare Research Collaboration
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Health policy, Dermatology
Keywords:	Dermatological tumours < DERMATOLOGY, Adverse events < THERAPEUTICS, Clinical Decision-Making, Surgical dermatology < DERMATOLOGY, Surgical pathology < PATHOLOGY, Patient-Centered Care



# **Impact of alternative diagnostic labels for melanoma in-situ on management choices and psychological outcomes: protocol for an online randomised study.**

Zhuohan Wu<sup>1</sup>, Brooke Nickel<sup>1,2</sup>, Farzaneh Boroumand<sup>1,3</sup>, David Elder<sup>4</sup>, Peter Ferguson<sup>5,6</sup>, Richard A. Scolyer<sup>5,6,7,8</sup>, Blake O'Brien<sup>9</sup>, Raymond Barnhill<sup>10</sup>, Adewole S Adamson<sup>11</sup>, Alexander C.J. van Akkooi<sup>5,12</sup>, Jon Emery<sup>13</sup>, Lisa Parker<sup>7,8,14</sup>, Donald Low<sup>15</sup>, Cynthia Low<sup>15</sup>, Elspeth Davies<sup>16</sup>, Sherrie Liu<sup>17</sup>, Stacey Lewis<sup>17</sup>, Bella Spongberg-Ross<sup>17</sup>, Katy JL Bell<sup>1,2</sup>

<sup>1</sup>Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

<sup>2</sup>Wiser Healthcare Research Collaboration, Sydney, NSW, Australia

<sup>3</sup>School of Mathematical and Physical Sciences, Macquarie University, NSW, Australia

<sup>4</sup>Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia

<sup>5</sup>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

<sup>6</sup>Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia

<sup>7</sup>Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

<sup>8</sup>Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia

<sup>9</sup>Sullivan Nicolaides Pathology, Brisbane, QLD, Australia

23 <sup>10</sup> Department of Translational Research, Institut Curie, Paris Sciences and Lettres  
24 Research University, and Faculty of Medicine University of Paris Descartes, Paris,  
25 France  
26 <sup>11</sup>Department of Internal Medicine (Division of Dermatology), The University of  
27 Texas at Austin Dell Medical School, Austin, TX 78701, USA  
28 <sup>12</sup> Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology,  
29 <sup>13</sup> Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia  
30 <sup>14</sup>Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia  
31 <sup>15</sup> Cancer Voices New South Wales, NSW, Australia  
32 <sup>16</sup> Patient Advocate, Cambridge, UK  
33 <sup>17</sup> Health Consumers New South Wales, NSW, Australia  
34  
35 **Corresponding Author and guarantor:** Katy Bell [katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

## Abstract

## Introduction

A diagnosis of melanoma in-situ presents negligible risk to a person's lifespan or physical wellbeing, but existing terminology makes it difficult for patients to distinguish these from higher risk invasive melanomas. This study aims to explore whether using an alternative label for melanoma in situ may influence patients' management choices and anxiety levels.

## Methods and Analysis

This study is a between-subjects randomised online experiment, using hypothetical scenarios. Following consent, eligible participants will be randomised 1:1:1 to three labels: "melanoma in situ" (control), "low-risk melanocytic neoplasm" (intervention 1) and "low-risk melanocytic neoplasm, in situ" (intervention 2). The required sample size is 1668 people. The co-primary outcomes are (i) choice between no further surgery or further surgery to ensure clear histological margins greater than 5 mm, and (ii) choice between patient initiated clinical follow up when needed (patient-led surveillance) and regular routinely scheduled clinical follow-up (clinician-led surveillance). Secondary outcomes include diagnosis anxiety, perceived risk of invasive melanoma and of dying from melanoma, and management choice anxiety (after surgery choice and follow-up choice). We will make pairwise comparisons across the three diagnostic label groups using regression models (univariable and multivariable).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

57     **Ethics and Dissemination**

58     The study has been registered with the Australian New Zealand Clinical Trials  
59     Registry (ACTRN12624000740594). Ethics approval has been received from The  
60     University of Sydney Human Research Ethics Committee (2024/HE000019). Results  
61     of the study will be published in a peer-reviewed medical journal and a plain language  
62     summary of the findings will be shared on the Wiser Healthcare publications page  
63     <https://www.wiserhealthcare.org.au/category/publications/>.

65     **Strengths and Limitations of This Study**

- 66         • The randomised design enables robust comparison of diagnostic labels on  
67             decision-making and psychological outcomes.
- 68         • The study has been co-designed with patients, members of the public, and  
69             clinicians to ensure labels and evidence are relevant to end-users.
- 70         • The large online randomised study is representative of adults in the Australian  
71             community.
- 72         • The study’s hypothetical nature limits its ability to capture real patients after  
73             an actual melanoma in situ diagnosis (or alternative label).
- 74         • The study does not explore the potential for recalibration of diagnostic  
75             thresholds using existing labels, the impact of diagnostic labels on actual  
76             patient or clinician decisions, or the impact of detailed risk information on  
77             diagnostic labels, all of which are areas for future research.

## INTRODUCTION

Melanoma incidence and mortality trajectories in Australia and other countries show a classic epidemiologic signature of overdiagnosis<sup>1</sup>: steeply increasing incidence curves coupled with flat mortality trends<sup>2-6</sup>. While aging populations may lead to a small real increase in melanoma incidence<sup>7</sup>, much of the increase is likely overdiagnosis<sup>2-6</sup>. This appears to be largely driven by increased diagnosis of melanoma in situ<sup>2 4 8</sup>, which in Australia is now diagnosed over twice as frequently as invasive melanoma<sup>9</sup>. Similar findings have been found for melanoma in the US (diagnosed at least as frequently as invasive melanoma)<sup>3</sup> and Denmark (diagnosed over half as frequently as invasive melanoma)<sup>10</sup>.

Multiple evidence lines indicate that melanoma in situ is a risk factor for invasive melanoma rather than an obligate precursor<sup>3 9 11 12</sup>. Overdiagnosis is partly driven by lowering the diagnostic threshold over the years, such that the same lesion that was called benign in the past, would now be labeled melanoma in situ<sup>12</sup>. Concerns about litigation may also be driving a tendency to interpret melanocytic lesions as a more severe diagnosis<sup>13</sup> particularly in partial biopsies or where the lesion extends to the surgical margins. Harms stemming from melanoma overdiagnosis include physical, psychosocial, and economic dimensions<sup>14</sup>. Physical harms can include overtreatment, repeat skin biopsies<sup>15</sup>, scarring<sup>15</sup>, pain, infection, and/or functional impairment. Psychological harms include anxiety and fear<sup>16 17</sup>, with many patients perceiving they

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

99 have a high risk of dying from melanoma, when their actual risk is much lower (and  
100 risk all-cause mortality is actually lower than the population average)<sup>18</sup>. These  
101 psychological harms can manifest as anxiety about being outdoors, fear of cancer  
102 recurrence, or guilt for past UV exposure causing melanoma<sup>5</sup>. Social harms include  
103 impacts of the diagnosis on loved ones, and on patients’ social networks<sup>15</sup>. Economic  
104 harms include treatment costs for the immediate diagnosis, and for future long term  
105 clinical surveillance. These incur substantial financial costs to both the health system  
106 and patient (as out-of-pocket costs), as well as opportunity costs for both clinician  
107 time and patient time. There is also a possible denial of life insurance as the person is  
108 now identified as a cancer survivor by many insurance companies<sup>3</sup>.  
109  
110 One possible solution is to consider a new label for melanoma in situ without the  
111 word “melanoma”<sup>12</sup>. This might help patients recognize the lower risk of this type of  
112 lesion<sup>18</sup>, and help to reduce the potential psychological harm. It may also pave the  
113 way for the de-escalation of treatment <sup>19</sup> and surveillance<sup>20-22</sup>. Evidence from other  
114 cancer contexts, including thyroid<sup>23</sup>, breast<sup>24</sup>, and prostate<sup>25</sup> lesions, suggests that new  
115 diagnostic labels may beneficially impact psychological outcomes and management  
116 decisions<sup>26</sup>. We seek to build on these findings by investigating the potential impacts  
117 of new labels for melanoma in situ. To ensure relevance of our findings to end-users,  
118 we will test alternative labels for melanoma in situ that were chosen by our co-  
119 Investigators representing clinicians, patients, and the public. Alternative label(s) need

to be acceptable to both patients and clinicians, and convey the low, but not zero, risk of future invasive melanoma. This study aims to explore whether using an alternative diagnostic label to communicate a hypothetical melanoma in situ diagnosis influences management choice and level of anxiety among Australian adults.

## METHODS AND ANALYSIS

### *Study design*

An online randomised study of Australian community members will be run, with participants randomised to receive one of three hypothetical scenarios about the diagnosis of a melanoma in situ. Each group will be presented with a different diagnostic label, and we will survey participants about their preferred choices of management for that diagnosis, their level of anxiety about that diagnosis and their level of anxiety about their management choices.

This study is a between-subjects randomised online experiment. Following consent, eligible participants will be randomised 1:1:1 to “melanoma in situ” (control), “low risk melanocytic neoplasm” (intervention label 1), and “low risk melanocytic neoplasm, in situ” (intervention label 2). The co-primary outcomes and secondary outcomes will be compared across randomised groups.

There will be an equal probability of being assigned to each of the 3 groups, and we expect approximately equal numbers per group. We will use Qualtrics survey software to randomly allocate participants into groups, present the scenarios, survey

141 questions and collect data on the outcomes<sup>27</sup>. Our participants flow diagram present a  
142 summary of the randomisation of participants into the allocated control and  
143 intervention arms (Figure 1).

145 ***Eligibility criteria***

146 Participants will be eligible if they are: 40 years or older, understand written English,  
147 and reside in Australia. Participants will be excluded if they have a history of  
148 melanoma (invasive or in-situ).

150 ***Recruitment and data collection.***

151 Participants will be recruited from the general Australian public through an  
152 independent social research company (Dynata), which has a panel of 600,000  
153 participants whose demographic characteristics align closely with those of the  
154 national population. Dynata has a points system in which participants receive points  
155 after completing surveys. The points can then be used to redeem vouchers, cash, or  
156 other rewards. Stratified sampling will be used, with quotas in place for gender (50%  
157 male, 50% female or other), age (25% for each of: 40-29 years, 50-59 years, 60-69  
158 years, 70 years or older, +/- 15% allowed for first three age groups and +/-30% for  
159 oldest age group)<sup>28</sup>, education (50% high school or less, 50% more than high school,  
160 +/-15% allowed), and State or Territory of residence (quotas proportionate to  
161 Australian population, +/-5% allowed: New South Wales 31.3%, Victoria 25.6%,

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Queensland 20.5%, South Australia 6.9%, Western Australia 10.9%, Tasmania 2.1%, Northern Territory 0.9%, and Australian Capital Territory 1.7% <sup>29</sup>).

Participants who agree to participate in the study will complete an online Qualtrics survey managed by the research team. Only eligible participants will proceed to the randomisation step. The survey will capture baseline data and characteristics of participants including socio-demographic details including their age, location, health literacy, and personal and family history of any cancer, and participant responses on outcome measures. The survey questions are presented in the Supplement.

All data will be collected via Qualtrics software and hosted on The University of Sydney secure server. Information will be de-identified and we will not be able to link the survey back to participants. The non-identifiable data will be downloaded for analysis and stored within The University of Sydney's Research Data Store.

#### ***Determination of alternative labels to be tested.***

We undertook a targeted literature search in September 2023 by retrieving forward and backward citation searches of four key papers on the topic<sup>5 12 26 30</sup>. We used the automated tool 'Spider Cite'<sup>31</sup>) to identify records, and Covidence to screen title, abstract and full-texts<sup>32</sup>. Of 593 unique records retrieved, we screened the full text of 27, and included 7 papers describing 9 alternative labels (see Box 1).

Using short online questionnaires implemented in Qualtrics<sup>27</sup>, we then ran three rounds of surveys with the 9 international Clinician co-Investigators (with expertise in

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

dermatopathology, dermatology, surgical oncology, primary care, and radiation oncology), and 6 Patient/Public co-Investigators (two with lived experience of a melanoma diagnosis and four without a history of melanoma) to determine choice of alternative labels. This resulted in the final choice of two alternative labels that we will test in the online survey: *low-risk melanocytic neoplasm* and *low-risk melanocytic neoplasm, in situ*.

**Interventions**

Participants will be randomised using Qualtrics randomisation software to receive one of three hypothetical scenarios. They will not be blinded. In each scenario, the participant will be told that the results of their recent skin surgery indicates a particular diagnosis. Group 1 (the control group) will be told they have a *melanoma in situ*. Group 2 will be told they have a *low-risk melanocytic neoplasm*. Group 3 will be told they have a *low-risk melanocytic neoplasm, in situ*. We will not provide further explanation of what low-risk means.

**Primary and Secondary Outcomes**

Primary and secondary outcomes are described in Table 1. The co-primary outcomes are (i) participant’s choice of surgical management option: no further surgery vs further surgery (to achieve pathology margins greater than 5 mm), and (ii) follow-up management option: patient led surveillance (self-skin examination with patient-

initiated clinic visits) vs clinician led surveillance (six monthly routinely scheduled clinic visits).

The first co-primary outcome on surgical management choice reflects recent retrospective analyses that have found that narrower margins are likely to be as safe as margins currently recommended in guidelines in small melanoma in situ<sup>33</sup>. Indeed very narrow histological clearance ( $\geq 1\text{mm}$ ) appears to be safe for melanoma in situ of the trunk and limbs<sup>34</sup>. The new MPATH-Dx V2.0 melanocytic lesion classification scheme recommends that provided margins are not involved, clinicians may consider not re-excising class II lesions – which includes melanoma in-situ<sup>35</sup>. The second co-primary outcome on follow-up management choice centres around patient-led surveillance (also called patient-initiated follow-up) as an alternative model of follow-up for cancer survivors to routinely scheduled clinic appointments<sup>36</sup>. Among people diagnosed and treated for early stage melanoma, patient-led surveillance is being evaluated in the MEL-SELF randomized controlled trial. Here, this model of care includes: training in self-skin examination, digital technologies to record and take images of concerning lesions (using a mobile dermatoscope), online system for submitting images for remote review by a dermatologist, and advice on whether urgent clinical review may be needed (teledermatology)<sup>37</sup>.

Secondary outcomes are: diagnosis anxiety, perceived lifetime risk of invasive melanoma, perceived lifetime risk of dying from melanoma, management choice anxiety, and open-text explanation of management choices (free text input).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

225  
  
226  
  
227  
  
228  
  
229  
  
230  
  
231  
  
232  
  
233  
  
234  
  
235  
  
236  
  
237  
  
238  
  
239  
  
240  
  
241  
  
242  
  
243  
  
244  
  
245

**Sample size**

We estimated a sample size of 1668 participants with 556 participants per group in the study, which would provide 80% power ( $1 - \beta$ ) to detect a pairwise difference in the proportion of choosing no further surgery, and 89% power to detect a pairwise difference in the proportion in choosing patient-led surveillance as small as 10%. The assumptions are: 50% would choose no further surgery (most conservative assumption) and 35%<sup>22</sup> would choose patient-led surveillance in the control label condition, a 5% dropout rate,  $\alpha = 0.05$ , the normal approximation to the binomial distribution, and the standard formula for comparing proportions in independent equal-sized groups.

**Analysis**

The analysis will focus on assessing the impact of different diagnostic labels for melanoma in situ on participants' psychological responses and healthcare decisions. Data analysts will be blinded to intervention assignment. For both co-primary outcomes, we will compare the proportion chosen for each management option. For first four secondary outcomes, we will compare summary statistical measures (means or medians) across randomised groups. For the last outcome, we will use thematic framework methods of qualitative data.

The analysis will adhere to the intention-to-treat principle, and participant data will be analyzed according to their randomly assigned diagnostic label group, regardless of adherence to the study protocol. The number of participant responses included in each analysis will be presented for each outcome. We will summarize categorical data for the randomised groups using counts and percentages, and continuous data using the minimum and maximum, mean, and standard deviation (SD) or median and interquartile range (IQR).

Statistical analyses will be conducted within a superiority framework to make pairwise comparisons across the three diagnostic label groups. Binary outcomes will be analyzed using logistic regression. Continuous outcomes will be analyzed using linear regression. For the cancer worry outcome, we will compare changes in worry across randomised groups by including baseline scores as a covariate in the regression model. Effect estimates for all primary and secondary outcomes will be presented with associated 95% confidence intervals (CI). All hypothesis tests will be two-sided with a significance level ( $\alpha$ ) of 5%. The potential for participants' health literacy to act as an effect modifier of intervention effects will be explored.

We will estimate unadjusted and adjusted effects using the relevant regression model. These will include variables used in sampling strata: age, education, geographic location (by state/territory). Prognostic factors will be measured through the baseline

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

questionnaire, and include baseline anxiety levels, sun exposure behavior, prior diagnosis of melanoma, diagnosis of melanoma in a family member. The effects of participants' health literacy on intervention effects will also be explored as a potential confounder.

***Planned start and end dates for the study***

The anticipated date of first participant enrolment was 01 July 2024 and the anticipated date of last data collection completion was 01 August 2024 (see Australian New Zealand Clinical Trials Registry, ID: ACTRN12624000740594)

***Patient and public involvement***

Two authors have lived experience of a melanoma diagnosis (one had MIS and one had a thin stage I invasive melanoma), and four authors are members of the public. Two authors are affiliated with Cancer Voices NSW, one author is a patient researcher from Cambridge UK, and three authors are affiliated with Health Consumers NSW.

**Ethics and Dissemination**

Ethics approval of this project was provided by the University of Sydney on 06 May 2024 (No. 2024/HE000019). The study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12624000740594). Updates to the protocol will be uploaded to the registry and identified by version number. As this study is an online randomised experiment which includes a hypothetical

scenario, we do not anticipate significant adverse events because of the trial interventions or conduct. Participants are reminded at several points before and after the study as part of the participant information, consent and debrief processes that the nature of the study is hypothetical, that none of the information relates to their actual health or wellbeing, and that researchers do not have access to their actual medical histories or information. The debriefing content also includes links to relevant resources for participants who wish to find out more.

#### **Data availability statement**

The research team will have access to the final dataset. Access may be granted to other researchers on reasonable request. No contractual agreements limit the disclosure of data to other investigators. The findings of the study will be published in a peer-reviewed medical journal. A lay summary of the findings will be published via permanent link at the Wiser Healthcare publications page.

#### **Contributors**

ZW co-led drafting of the manuscript, led drafting of the study questionnaire and application to the Human Research Ethics Committee, and assisted with the targeted literature review (full text screening and data extraction). BN and KB conceptualized the research, provided methodological expertise. KB, who is the guarantor, led the targeted literature review and the Clinician and Consumer Investigator survey to decide the choice of alternative labels, and co-led drafting of the manuscript. FB calculated the sample size. BN, FB DE, PF, RS, BO, RB, AvA, AA, JE, LP, DL, CL,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

ED, SLi, SLe, BSR and KB revised the manuscript. All authors read, contributed to, and approved the final manuscript.

**Funding**

National Health and Medical Research Council of Australia (NHMRC) Centre for Research Excellence Grant (2021/GNT2006545)  
Brooke Nickel: NHMRC Investigator Grant (2020/GNT1113532)  
RAS: NHMRC Investigator Grant (2022/GNT2018514)  
Katy Bell: NHMRC Investigator Grant (2019/GNT1174523)

**Declaration of Interests**

RAS has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline.  
AvA received Advisory Board/Consultancy Honoraria from 4SC AG, Amgen, Bristol-Myers Squibb, Merck Serono-Pfizer, MSD-Merck, Neracare, Novartis, Pierre Fabre, Sanofi, Sirius Medical, SkylineDX and Research Grants from Amgen, Merck Serono-Pfizer, SkylineDX.  
All other authors have no conflicts of interest to declare.

**References:**

1. Welch HG, Kramer Barnett S, Black William C. Epidemiologic Signatures in Cancer. *New England Journal of Medicine* 2019;381(14):1378-86. doi: 10.1056/NEJMSr1905447
2. Glasziou PP, Jones MA, Pathirana T, et al. Estimating the magnitude of cancer overdiagnosis in Australia. *Med J Aust* 2020;212(4):163-68. doi: 10.5694/mja2.50455 [published Online First: 2019/12/21]
3. Welch HG, Mazer BL, Adamson AS. The Rapid Rise in Cutaneous Melanoma Diagnoses. *N Engl J Med* 2021;384(1):72-79. doi: 10.1056/NEJMSb2019760 [published Online First: 2021/01/07]
4. Adewole SA, Geetanjali N, Mark AJ, et al. Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method. *BMJ Evidence-Based Medicine* 2024;bmjebm-2023-112460. doi: 10.1136/bmjebm-2023-112460
5. Adamson AS, Suarez EA, Welch HG. Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. *JAMA Dermatology* 2022;158(4):426-31. doi: 10.1001/jamadermatol.2022.0139
6. Mille Falk B, Emma Grundtvig G, John Brandt B. Overdiagnosis in malignant melanoma: a scoping review. *BMJ Evidence-Based Medicine* 2024;29(1):17. doi: 10.1136/bmjebm-2023-112341
7. Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. *The Lancet* 2023;402(10400):485-502. doi: 10.1016/S0140-6736(23)00821-8

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

350 8. Whiteman DC, Olsen CM, MacGregor S, et al. The effect of screening on  
351 melanoma incidence and biopsy rates. *Br J Dermatol* 2022;187(4):515-22. doi:  
352 10.1111/bjd.21649 [published Online First: 2022/05/10]

353 9. Olsen CM, Pandeya N, Rosenberg PS, et al. Incidence of in Situ vs Invasive  
354 Melanoma: Testing the "Obligate Precursor" Hypothesis. *J Natl Cancer Inst*  
355 2022;114(10):1364-70. doi: 10.1093/jnci/djac138 [published Online First:  
356 2022/09/01]

357 10. Nielsen JB, Kristiansen IS, Thapa S. Increasing melanoma incidence with  
358 unchanged mortality: more sunshine, better treatment, increased diagnostic activity,  
359 overdiagnosis or lowered diagnostic threshold? *British Journal of Dermatology*  
360 2024;ljae175. doi: 10.1093/bjd/ljae175

361 11. Elder DE. Obligate and Potential Precursors of Melanoma. *JNCI: Journal of the*  
362 *National Cancer Institute* 2022;114(10):1320-22. doi: 10.1093/jnci/djac139

363 12. Semsarian CR, Ma T, Nickel B, et al. Do we need to rethink the diagnoses  
364 melanoma in situ and severely dysplastic naevus? *British Journal of Dermatology*  
365 2022;186(6):1030-32. doi: 10.1111/bjd.21010

366 13. Titus LJ, Reisch LM, Tosteson ANA, et al. Malpractice Concerns, Defensive  
367 Medicine, and the Histopathology Diagnosis of Melanocytic Skin Lesions. *Am J Clin*  
368 *Pathol* 2018;150(4):338-45. doi: 10.1093/ajcp/aqy057 [published Online First:  
369 2018/07/15]

- 1  
2  
3  
4 370 14. Bell KJL, Nijsten T. Melanoma overdiagnosis: why it matters and what can be  
5  
6 371 done about it. *Br J Dermatol* 2022;187(4):459-60. doi: 10.1111/bjd.21750 [published  
7  
8  
9 372 Online First: 2022/08/06]
- 10  
11 373 15. Elspeth D. Informed by research, transformed by research. *BMJ Evidence-Based*  
12  
13  
14 374 *Medicine* 2024;29(1):62. doi: 10.1136/bmjebm-2023-112646
- 15  
16  
17 375 16. Bell KJL, Mehta Y, Turner RM, et al. Fear of new or recurrent melanoma after  
18  
19 376 treatment for localised melanoma. *Psycho-Oncology* 2017;26(11):1784-91. doi:  
20  
21 377 <https://doi.org/10.1002/pon.4366>
- 22  
23  
24 378 17. Mahama AN, Haller CN, Labrada J, et al. Lived Experiences and Fear of Cancer  
25  
26  
27 379 Recurrence Among Survivors of Localized Cutaneous Melanoma. *JAMA Dermatol*  
28  
29 380 2024;160(5):495-501. doi: 10.1001/jamadermatol.2023.6158 [published Online First:  
30  
31 381 2024/02/14]
- 32  
33  
34 382 18. Patel VR, Roberson ML, Pignone MP, et al. Risk of Mortality After a Diagnosis  
35  
36  
37 383 of Melanoma In Situ. *JAMA Dermatology* 2023;159(7):703-10. doi:  
38  
39 384 [10.1001/jamadermatol.2023.1494](https://doi.org/10.1001/jamadermatol.2023.1494)
- 40  
41  
42 385 19. Zijlker LP, Eggermont AMM, van Akkooi ACJ. The end of wide local excision  
43  
44  
45 386 (WLE) margins for melanoma ? *European Journal of Cancer* 2023;178:82-87. doi:  
46  
47 387 <https://doi.org/10.1016/j.ejca.2022.10.028>
- 48  
49  
50 388 20. Moncrieff MD, Bastiaannet E, Underwood B, et al. Follow-up Schedule for  
51  
52  
53 389 Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study):

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

390 An International Phase III Randomized Clinical Trial. *Annals of Surgery*  
391 2022;276(4):e208-e16.

392 21. Lim W-Y, Morton RL, Turner RM, et al. Patient Preferences for Follow-up After  
393 Recent Excision of a Localized Melanoma. *JAMA Dermatology* 2018;154(4):420-27.  
394 doi: 10.1001/jamadermatol.2018.0021

395 22. Drabarek D, Ackermann D, Medcalf E, et al. Acceptability of a Hypothetical  
396 Reduction in Routinely Scheduled Clinic Visits Among Patients With History of a  
397 Localized Melanoma (MEL-SELF): Pilot Randomized Clinical Trial. *JMIR Dermatol*  
398 2023;6:e45865. doi: 10.2196/45865

399 23. Nickel B, Barratt A, McGeechan K, et al. Effect of a Change in Papillary Thyroid  
400 Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized  
401 Crossover Trial. *JAMA Otolaryngol Head Neck Surg* 2018;144(10):867-74. doi:  
402 10.1001/jamaoto.2018.1272 [published Online First: 2018/10/20]

403 24. McCaffery K, Nickel B, Moynihan R, et al. How different terminology for ductal  
404 carcinoma in situ impacts women’s concern and treatment preferences: a  
405 randomised comparison within a national community survey. *BMJ Open*  
406 2015;5(11):e008094. doi: 10.1136/bmjopen-2015-008094

407 25. Berlin A, Ramotar M, Santiago AT, et al. The influence of the “cancer” label on  
408 perceptions and management decisions for low-grade prostate cancer. *JNCI: Journal*  
409 *of the National Cancer Institute* 2023;115(11):1364-73. doi: 10.1093/jnci/djad108

26. Nickel B, Moynihan R, Barratt A, et al. Renaming low risk conditions labelled as cancer. *Bmj* 2018;362:k3322. doi: 10.1136/bmj.k3322 [published Online First: 2018/08/14]
27. Qualtrics. Qualtrics 2024 [Available from: <https://www.qualtrics.com/>.
28. Australian Bureau of Statistics (ABS). Regional population by age and sex 2023 [Available from: <https://www.abs.gov.au/statistics/people/population/regional-population-age-and-sex/latest-release> accessed 15 October 2024.
29. Australian Bureau of Statistics (ABS). National, state and territory population 2023 [Available from: <https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2023> accessed 15 October 2024.
30. Elmore JG, Barnhill RL, Elder DE, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. *BMJ* 2017;357:j2813. doi: 10.1136/bmj.j2813 [published Online First: 20170628]
31. Clark J, Glasziou P, Del Mar C, et al. A full systematic review was completed in 2 weeks using automation tools: a case study. *J Clin Epidemiol* 2020;121:81-90. doi: 10.1016/j.jclinepi.2020.01.008 [published Online First: 20200128]
32. Veritas Health Innovation. Covidence systematic review software [Available from: [www.covidence.org](http://www.covidence.org).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

429 33. Sun C, Lim A, De'Ambrosio B, et al. Recurrence Rate of Small Melanoma In Situ  
430 on Low-Risk Sites Excised With 5-mm Excisional Margin. JAMA Dermatology  
431 2024;160(8) doi: 10.1001/jamadermatol.2024.1878

432 34. Smith H, Hussain W. Is it time we changed the way we manage melanoma in situ  
433 of the trunk and limbs? British Journal of Dermatology 2023;188(5):685-87. doi:  
434 10.1093/bjd/ljad031

435 35. Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic  
436 Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for  
437 Melanocytic Lesions: A Consensus Statement. JAMA Netw Open  
438 2023;6(1):e2250613. doi: 10.1001/jamanetworkopen.2022.50613 [published Online  
439 First: 20230103]

440 36. Dretzke J, Chaudri T, Balaji R, et al. A systematic review of the effectiveness of  
441 patient-initiated follow-up after cancer. Cancer Medicine 2023;12(18):19057-71. doi:  
442 <https://doi.org/10.1002/cam4.6462>

443 37. Ackermann DM, Dieng M, Medcalf E, et al. Assessing the Potential for Patient-  
444 led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot  
445 Randomized Clinical Trial. JAMA Dermatology 2022;158(1):33-42. doi:  
446 10.1001/jamadermatol.2021.4704

447 38. Vuong K, Armstrong BK, Weiderpass E, et al. Development and External  
448 Validation of a Melanoma Risk Prediction Model Based on Self-assessed Risk

- Factors. JAMA Dermatology 2016;152(8):889-96. doi:  
10.1001/jamadermatol.2016.0939
39. World Health Organization. Wellbeing measures in primary health care/the  
DepCare Project: report on a WHO meeting: Stockholm, Sweden, 12–13 February  
1998: World Health Organization. Regional Office for Europe, 1998.
40. Scherer LD, Zikmund-Fisher BJ. Eliciting medical maximizing-minimizing  
preferences with a single question: development and validation of the MM1. Medical  
Decision Making 2020;40(4):545-50.
41. Morris NS, MacLean CD, Chew LD, et al. The Single Item Literacy Screener:  
evaluation of a brief instrument to identify limited reading ability. BMC family  
practice 2006;7:1-7.
42. Schwarzer R, Jerusalem M. Generalized self-efficacy scale. J Weinman, S Wright,  
& M Johnston, Measures in health psychology: A user's portfolio Causal and control  
beliefs 1995;35:37.
43. Davey HM, Barratt AL, Butow PN, et al. A one-item question with a Likert or  
Visual Analog Scale adequately measured current anxiety. Journal of clinical  
epidemiology 2007;60(4):356-60.
44. Dillard AJ, Ferrer RA, Welch JD. Associations between narrative transportation,  
risk perception and behaviour intentions following narrative messages about skin  
cancer. Psychology & Health 2017;33(5):573-93. doi:  
10.1080/08870446.2017.1380811

**Box 1: Process to select alternative labels to melanoma in situ for testing**

- In the first-round surveys Clinician and Patient/Public co-Investigators indicated their ranking the 7 labels identified in the targeted literature search, and 2 additional labels in order of preference. The potential alternative labels from the literature search were: Melanocytic neoplasm of low malignant potential (8,24,25), Melanocytic neoplasm, Atypical neoplasm" (25), Severe or High-Grade Melanocytic Dysplasia, Superficial Atypical Melanocytic Proliferation of Uncertain Malignant Significance (SAMPUS) (26–28), Melanocytic Tumor of Uncertain Malignant Potential (MELTUMP), Melanocytoma (28). The two additional labels suggested by the research team were: low-risk melanocytic neoplasm and low-risk melanocytic lesion.
- In the second round surveys, co-Investigators indicated their preferred ranking of the top three choices from round 1 and two new labels suggested in round 1: Low-risk melanocytic neoplasm, Low-risk melanocytic lesion, and Melanocytic neoplasm of low malignant potential, Melanocytic intraepithelial neoplasia, and In situ melanocytic neoplasm.
- In the third round surveys, co-Investigators indicated their preferred ranking of the top two choices from round 2, and three new labels suggested in round 2: In situ melanocytic neoplasm, Low-risk melanocytic neoplasm, In situ melanocytic neoplasm, low risk, low-risk melanocytic neoplasm, in-situ, and dysplastic naevus.

The two highest ranked labels, chosen as the alternative labels to test in the online experiment, were: “*low-risk melanocytic neoplasm*” and “*low-risk melanocytic neoplasm, in-situ*”.

471

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

472 **Table 1. Participant characteristics and outcome measures.**

Variable	Measure
Participant Characteristics	
Melanoma risk	Melanoma risk prediction based self-assessed risk factors <sup>38</sup>
General mood and wellbeing.	WHO (Five) Well-Being Questionnaire. <sup>39</sup>
Medical minimiser/maximiser.	Single-Item Maximiser/Minimiser Elicitation Question (MM1). <sup>40</sup>
Health literacy.	Single Item Literacy Screener (SILS). <sup>41</sup>
Melanoma worry.	Direct choice between specified options, one choice possible.
Self-efficacy.	Generalized Self-Efficacy Scale (GSE). <sup>42</sup>
Primary Outcomes	
Co-primary outcomes are choices for two management decisions. 1. Choice of further surgery: • No further surgery • Further surgery to ensure margins >5 mm from lesion on pathology 2. Choice of follow-up: • Patient led surveillance: self-monitoring with patient-initiated clinic visits as needed • Clinician led surveillance: six monthly routinely scheduled clinic visits	Direct choice between two management approaches for each co-primary outcome Choice of further surgery and choice of follow-up.
Secondary Outcomes	
Diagnosis anxiety (feelings)	Single-question Visual Analogue Scale (0-6). <sup>43 44</sup>
Experiential perceived risk (vulnerability)	Single-question Visual Analogue Scale (0-6). <sup>44</sup>
Perceived lifetime absolute risk of invasive melanoma	Single-question Visual Analogue Scale (0-100). <sup>44</sup>
Perceived lifetime comparative risk of invasive melanoma	Single-question Visual Analogue Scale (0-6). <sup>44</sup>

Perceived lifetime risk of dying from melanoma	Single-question Visual Analogue Scale (0-100).
Management choice anxiety.	Single-question Visual Analogue Scale (0-6). <sup>43</sup>
Open-text explanation of management choice.	Free text (optional)

473

474

For peer review only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1.** Study Consolidated Standards of Reporting Trials flow diagram for participants. Participants' selection inclusion criteria are age over 40, understanding written English and residing in Australia. Patients will be excluded if they have melanoma, or do not provide consent.

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figure 1. Study CONSORT flow diagram



**Landing Page ✓**

**Does the label for a low-risk melanocytic lesion influence management choice: a randomised experiment.**

Thank you for your interest in our study about low-risk melanocytic lesions.

In this study, you will be randomised to be shown one of three hypothetical scenarios following surgery on a mole, which will be followed by questions about management options and anxiety.

The study is being conducted by a team of researchers from The University of Sydney School of Public Health. The team members are:

- Professor Katy Bell (School of Public Health at the University of Sydney)
- Dr Brooke Nickel (School of Public Health at the University of Sydney)
- Mr Zhuohan Wu (School of Public Health at the University of Sydney)

Taking part in the study involves completing one online questionnaire which will take approximately 10 minutes to complete.

Being in this study is completely voluntary and you do not have to take part. Your decision on whether to participate will not affect your current or future relationship with the researchers or anyone else at the University of Sydney.

Please take the time to read through the Participant Information Statement below.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

If you are interested in taking part in this study, you will be asked to consent to take part by ticking the 'yes' box at the beginning of the questionnaire. By giving your consent to take part in this study, you are telling us that you:

- ✓ Understand what you have read in the Participant Information Statement.
- ✓ Agree to take part in the research study as outlined in Participant Information Statement.
- ✓ Agree to the use of your personal information as described.

When you have consented, you will fill out an online questionnaire that asks a series of questions, such as:

- Demographic questions, such as age, education, income level and relationship status.
- General health and cancer related questions.
- Melanoma and other cancer history related questions.

You will be randomised to read one of three **HYPOTHETICAL EXAMPLES** (these are made-up examples) in which different labels are used to explain a low-risk melanocytic skin lesion result. **Please note that you WILL NOT be receiving information or advice on any real mole check results or information about your actual health status.**

The hypothetical examples will be followed by questions about choice of management strategy and personal perspective.

Note that there is no back button. Please give your best answer to each question before moving on to the next.

1 **Pre-Survey PIS ✓**

5 You can click the link below to download the Participants Information Sheet for  
6 more information about this study.

9 [Participants Information Sheet](#)

13 **Pre-Survey Consent Form ✓**

18 Do you consent to take part in this study as described in the welcome page and  
19 Participants Information Sheet?

- 22 ☐ Yes  
23  
24 ☐ No  
25

30 **Section 1: Screening and Socio-Demographic ✓**

35 Have you been previously diagnosed with a melanoma?

- 37 ☐ Yes  
38  
39 ☐ No  
40

45 What is your age?

47

53 **Section 1.5: Screening and Socio-Demographic Part 2**

57 Which of the following best describes your current gender identify?

- ☐ Male
- ☐ Female
- ☐ Non-binary / gender fluid
- ☐ Different identify

Which Australian state or territory do you currently live in?

- ☐ New South Wales
- ☐ Victoria
- ☐ Australian Capital Territory
- ☐ Queensland
- ☐ South Australia
- ☐ Western Australia
- ☐ Northern Territory
- ☐ Tasmania

Where are you located? (please enter your post code)

What is your highest level of education?

- ☐ Year 10 or below
- ☐ Year 11
- ☐ Year 12
- ☐ Certificate I/II
- ☐ Certificate III/IV
- ☐ Advanced diploma/diploma
- ☐ Bachelor's degree
- ☐ Graduate diploma/graduate certificate
- ☐ Postgraduate degree (Masters or Doctorate)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

☐  Other - please specify:

What is your current employment status?

- ☐ Permanent or ongoing
- ☐ Fixed-term contract
- ☐ Casual/temporary (no paid sick leave or annual leave)
- ☐ Self-employed
- ☐ On paid leave (e.g. maternity leave)
- ☐ Unemployed
- ☐ Not working/not in the labour force (e.g. student, home duties, retired)

What was your total household income before taxes during the past 12 months?

- ☐ Less than AUD \$30,000
- ☐ Between AUD \$30,000 - \$49,999
- ☐ Between AUD \$50,000 - \$79,999
- ☐ Between AUD \$80,000 - \$99,999
- ☐ Between AUD \$100,000 - \$149,999
- ☐ Between AUD \$150,000 - \$199,999
- ☐ AUD \$200,000 or more
- ☐ Prefer not to say

Do you have private health insurance?

- ☐ Yes
- ☐ No
- ☐ Don't know

BMJ Open: first published as 10.1136/bmjopen-2024-089558 on 20 December 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1 Do you have a partner?

- 2
- 3 ☐ Spouse
- 4
- 5 ☐ De-facto partner
- 6
- 7 ☐ Partner who does not reside with you
- 8
- 9 ☐ No partner
- 10
- 11 ☐ Widowed
- 12
- 13 ☐ Divorced or separated
- 14
- 15 ☐  Other - please list:
- 16
- 17
- 18
- 19

20

21 Do you have children?

- 22
- 23 ☐ Yes
- 24
- 25 ☐ No
- 26
- 27 ☐ Prefer not to say
- 28
- 29
- 30

31

32

33 Are you of Aboriginal or Torres Strait Islander origin?

- 34
- 35 ☐ Aboriginal
- 36
- 37 ☐ Torres Strait Islander
- 38
- 39 ☐ Both Aboriginal and Torres Strait Islander
- 40
- 41 ☐ Neither Aboriginal or Torres Strait Islander
- 42
- 43 ☐ Prefer not to say
- 44
- 45
- 46
- 47
- 48

49 Were you born in Australia?

- 50
- 51 ☐ Yes
- 52
- 53 ☐ No
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1 What is your country of birth?  
2

- 3 ☐ UK  
4  
5 ☐ India  
6  
7 ☐ China  
8  
9 ☐ New Zealand  
10  
11 ☐ The Philippines  
12  
13 ☐  Other - please list:  
14  
15  
16  
17  
18

19 In which year did you move to Australia?  
20

21   
22  
23  
24  
25


26 What language do you mostly speak at home?  
27

- 28 ☐ English  
29  
30 ☐ Mandarin  
31  
32 ☐ Arabic  
33  
34 ☐ Cantonese  
35  
36 ☐ Vietnamese  
37  
38 ☐  Other - please list:  
39  
40  
41  
42  
43

44 What was your natural hair colour when you were 18 years of age  
45

- 46 ☐ Black  
47  
48 ☐ Brown  
49  
50 ☐ Fair or Blond  
51  
52 ☐ Red or Auburn  
53  
54  
55  
56  
57  
58  
59  
60

Looking at the image below, please select the option that approximately represents the number of moles on your body when you were aged 18 years, as best as you can remember.



- ☐ None
- ☐ Few moles
- ☐ Some moles
- ☐ Many moles

Have you ever used a sunbed or sunlamp?

- ☐ Yes
- ☐ No

## Section 2: General Health Screening

Have you ever been diagnosed with any type of cancer?

- Page 39 of 48  
04/10/2024, 13:38
- ☐ Yes
- ☐ No
- ☐ Don't know

## Which type of cancer?

- ☐ Melanoma
- ☐ Skin (not melanoma)
- ☐ Prostate
- ☐ Breast
- ☐ Bowel
- ☐ Lung
- ☐ Lymphoma
- ☐  Other - please list:
- ☐ Don't know

## Section 2: General Health ✓

In general, would you say your health is ...

- ☐ Excellent
- ☐ Very good
- ☐ Good
- ☐ Fair
- ☐ Poor

Has a current or former partner or a close friend ever been diagnosed with cancer?

- ☐ Yes

☐ No

Which type of cancer?

☐ Melanoma

☐ Skin (not melanoma)

☐ Prostate

☐ Breast

☐ Bowel

☐ Lung

☐ Lymphoma

☐  Other - please list:

☐ Don't know

Has anyone in your close family ever been diagnosed with cancer?

☐ Yes

☐ No

☐ Don't know

Which type of cancer? Please tick all that apply

☐ Melanoma

☐ Skin (not melanoma)

☐ Prostate

☐ Breast

☐ Bowel

☐ Lung

☐ Lymphoma

☐  Other - please list:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

☐ Don't know

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

Who was this? Please tick all that apply

- 39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- ☐ Mother
- ☐ Father
- ☐ Sister
- ☐ Brother
- ☐ Daughter
- ☐ Son
- ☐  Other - please list:

How worried are you about developing melanoma?

- ☐ Not worried at all
- ☐ A bit worried
- ☐ Quite worried
- ☐ Very worried

Sometimes, medical action is clearly necessary and sometimes it is clearly not necessary.

Other times, reasonable people differ in their beliefs about whether medical action is needed.

In situations where it's not clear, do you tend to lean towards taking action or do you prefer to wait and see if action is needed?

Importantly, there is no right way to be.

- ☐ I strongly lean towards wait and see.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- ☐ I lean towards wait and see.
- ☐ I somewhat lean towards wait and see.
- ☐ I somewhat lean towards taking action.
- ☐ I lean towards taking action.
- ☐ I strongly lean towards taking action.

The following questions are related to how you have been feeling over the past two weeks. Please read each statement and then choose the most appropriate option regarding how you felt in the last two weeks.

	At no time	Some of the time	Less than half of the time	More than half of the time	Most of the time	All of the time
I have felt cheerful and in good spirits.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I have felt calm and relaxed.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I have felt active and vigorous.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I woke up feeling fresh and rested.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
My daily life has been filled with things that interest me.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please respond to the following statements.

	Not at all true	Hardly true	Moderately true	Mostly true
I can always manage to solve difficult problems if I try hard enough.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
If someone opposes me, I can find the means and	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Not at all true	Hardly true	Moderately true	Mostly true
ways to get what I want.				
It is easy for me to stick to my aims and accomplish my goals.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I am confident that I could deal efficiently with unexpected events.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thanks to my resourcefulness, I know how to handle unforeseen situations.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
	Not at all true	Hardly true	Moderately true	Mostly true
I can solve most problems if I invest the necessary effort.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I can remain calm when facing difficulties because I can rely on my coping abilities.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
When I am confronted with a problem, I can usually find several solutions.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
If I am in trouble, I can usually think of a solution.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I can usually handle whatever comes my way.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Section 3: Health Literacy ✓

How often do you need to have someone help you when you read instructions, pamphlets or other written material from your doctor or pharmacy?

☐ Always

☐ Often

☐ Sometimes

☐ Occasionally

☐ Never

## Randomized hypothetical labels

Please read the hypothetical information below and answer the questions that follow. You are asked to imagine as if the following information is true. Please answer how you would feel or react if you were in this situation, to the best of your ability.

You are at the doctor (GP) after you recently had a small surgery done to remove one of your moles.

The doctor has the pathology test results and says: "We found a **#{e://Field/Label}**. We removed it all, and also 3mm of normal skin around the **#{e://Field/Label}**."

## Section 5: Primary and Secondary Outcome Measures ✓

**Given the diagnosis of **#{e://Field/Label}**, how anxious do you feel?**

*Answer from Not at all anxious (0) to Extremely anxious(6).*

	Not at all			Extremely			
	0	1	2	3	4	5	6

**Given the diagnosis of **#{e://Field/Label}**, how vulnerable do you feel to developing invasive melanoma sometime in your life?**


*Answer from Not at all vulnerable (0) to Extremely vulnerable (6).*

Not at all

Extremely

0123456

Given the diagnosis of  $\{e://Field/Label\}$ , on a scale of 0–100%, what do you think your chances are of **developing** an invasive melanoma sometime in your life?




Given the diagnosis of  $\{e://Field/Label\}$ , what do you think your chances are of developing an invasive melanoma, compared to others of your age, gender, and skin colour?

Answer from Much lower chance (0) to Much higher chance (6).



Given the diagnosis of  $\{e://Field/Label\}$ , on a scale of 0 –100%, what do you think your chances are of **dying** from melanoma?



Please explain your reasoning behind the percentage you provided. [This question is optional]

Your doctor continues: "You now need to decide whether you would like us to do further surgery to remove more normal skin from around the scar, or whether you would prefer no further surgery at this time. I recommend either of these options as a reasonable choice and will organise whichever you prefer."

**Given the diagnosis of \${e://Field/Label}, which of these surgery management options would you choose?**

- ☐ Further surgery to remove more normal skin around the scar (so that the distance from the margins to the \${e://Field/Label} is greater than 5 mm)
- ☐ No further surgery

Please tell us how you decided on that surgery management option. What were the important factors that helped you decide? [This question is optional].

After making that surgery management choice, how anxious do you feel?  
*Answer from Not at all anxious (0) to Extremely anxious (6).*

Not at all					Extremely	
0	1	2	3	4	5	6

Your doctor further explains that there are also different options for follow-up: "You need to also decide whether you would like to book in for regular skin checks with me every 6 months, or you would like us to teach you how to check your skin yourself (with tele-dermatologist support) and book in with me only if needed. Again, I recommend either option as a reasonable choice, and will organise whichever one you prefer."

Given the diagnosis of **{e://Field/Label}**, which of these follow-up management options would you choose?

- ☐ My doctor does my skin check at regular 6 monthly appointments.
- ☐ I do my own skin checks with help from my partner/friend/relative (to check my back and other hard to see areas), and book in with my doctor when I need to.
  - I am taught how to examine my total body and am given a special imaging device that clips on my phone.
  - I have access to videos and online support to help me do skin checks and use the imaging device.
  - I can take images of any moles that concern me and send these to a dermatologist.
  - If the dermatologist is concerned, then I am booked in immediately for a skin check with my doctor.

Please tell us how you decided on that follow up management option. What were the important factors that helped you decide? [This question is optional].

After making that follow up management choice, how anxious do you feel?  
*Answer from Not at all anxious (0) to Extremely anxious (6).*

Not at all			Extremely			
0	1	2	3	4	5	6

Section 6: Debrief Statement ✓

You were a participant in this study which aimed to investigate how people would react to different information provision on diagnosis of a low-risk melanocytic lesion results by the label given to the melanocytic lesion.

During the study, you were asked to imagine a hypothetical scenario in which you are given a diagnosis result after having gone to a routine screening. You

were then asked to complete a series of survey questions.

You were randomised to receive one of three different hypothetical scenarios.

These three diagnosis scenarios were:

1. Diagnosis of a melanoma in situ.
2. Diagnosis of a low-risk melanocytic neoplasm.
3. Diagnosis of a low-risk melanocytic neoplasm, in situ.

The purpose of this study was to examine the impact of these different labels/diagnoses on preferred management strategy and psychological outcomes such as worry and health seeking intentions.

It is important to remember that this study was entirely hypothetical (made up). The study team does not have access to any of your medical history.

If you have any further questions regarding the study, feel free to contact Prof Katy Bell ([katy.bell@sydney.edu.au](mailto:katy.bell@sydney.edu.au))

For more information on melanoma and skin checks, please visit the following websites:

[Melanoma Institute Australia](#)

[Cancer Council - Melanoma](#)

We are conducting a follow-up study to explore individuals' experiences, concerns, and preferences regarding current and potential alternative labels for melanoma in situ. Would you be interested in participating in an interview

over the telephone or using web conferencing tools like Zoom or Microsoft Teams?

- ☐ Yes
- ☐ No

Thank you for your interest! Please provide your email address below so we can contact you to schedule the interview.

Section 7: Feedback ✓

Thank you for your participation in the survey. Your time and contribution is greatly appreciated. If you are interested in the results of the study, the results and a lay summary of the results will be published at the following permanent web page: [Wiser Healthcare publications](#)

Powered by Qualtrics

BMJ Open: first published as 10.1136/bmjopen-2024-089558 on 20 December 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.